Immunosuppressants, Oral
Therapeutic Class Review (TCR)

January 11, 2019

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management.

All requests for permission should be mailed to:

Magellan Rx Management
Attention: Legal Department
6950 Columbia Gateway Drive
Columbia, Maryland 21046

The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to PSTCREditor@magellanhealth.com.
## FDA-APPROVED INDICATIONS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Manufacturer</th>
<th>Prophylaxis Against Organ Rejection</th>
<th>Rheumatoid Arthritis</th>
<th>Refractory Plaque Psoriasis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Heart</td>
<td>Kidney</td>
<td>Liver</td>
</tr>
<tr>
<td>azathioprine (Azasan∗, Imuran®)1,2</td>
<td>generic, Salix, Sebela</td>
<td></td>
<td>X adjunctive</td>
<td></td>
</tr>
<tr>
<td>cyclosporine† (Sandimmune®)3</td>
<td>generic, Novartis</td>
<td>X adjunctive</td>
<td>X adjunctive</td>
<td>X adjunctive</td>
</tr>
<tr>
<td>cyclosporine, modified (Gengraf®8, Neoral®)4,5</td>
<td>generic, Abbvie, Novartis</td>
<td>X adjunctive</td>
<td>X adjunctive</td>
<td>X adjunctive</td>
</tr>
<tr>
<td>everolimus (Zortress®)6</td>
<td>Novartis</td>
<td></td>
<td>X adjunctive</td>
<td></td>
</tr>
<tr>
<td>mycophenolate mofetil (CellCept®)7</td>
<td>generic, Genentech</td>
<td>X adjunctive</td>
<td>X adjunctive</td>
<td>X adjunctive</td>
</tr>
<tr>
<td>mycophenolate sodium (Myfortic®)8</td>
<td>generic, Novartis</td>
<td></td>
<td>X adjunctive</td>
<td></td>
</tr>
<tr>
<td>sirolimus§ (Rapamune®)9</td>
<td>generic, Wyeth/ Pfizer</td>
<td></td>
<td>X adjunctive</td>
<td></td>
</tr>
<tr>
<td>tacrolimus** (Prograf®)10</td>
<td>generic, Astellas</td>
<td>X adjunctive</td>
<td>X adjunctive</td>
<td>X adjunctive</td>
</tr>
<tr>
<td>tacrolimus extended-release** (Astagraf XL®)11</td>
<td>Astellas</td>
<td></td>
<td>X adjunctive</td>
<td></td>
</tr>
<tr>
<td>tacrolimus extended-release** (Envarsus XR®)12</td>
<td>Veloxis</td>
<td></td>
<td>X adjunctive</td>
<td></td>
</tr>
</tbody>
</table>

* Azasan is a branded generic for Imuran; it was approved via an Abbreviated New Drug Application (ANDA) with Imuran as the reference product.
† Cyclosporine may also be used for the treatment of chronic rejection in patients previously treated with other immunosuppressive agents.
‡ Gengraf is a branded generic for Neoral; it was approved via ANDA with Neoral as the reference product.
§ Approved for those at low to moderate immunologic risk; use in combination with basiliximab, cyclosporine (reduced doses), and corticosteroids.
¶ Sirolimus (Rapamune) is also approved for the treatment of patients with lymphangioleiomyomatosis (LAM).
** Tacrolimus products (Prograf, Astagraf XL, Envarsus XR) are not interchangeable or substitutable.
†† Tacrolimus extended-release (Envarsus XR) is approved for the prophylaxis of organ rejection in kidney transplant patients and for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants.

Oral immunosuppressants included in the above table, when used in the setting of organ transplant, are rarely utilized as single agents; rather, they are used in various combinations, along with corticosteroids and other appropriate agents based on product labeling, established literature, and local protocols.

Cyclosporine is also available as a 0.05% ophthalmic emulsion for the treatment of xerophthalmia, this formulation and indication will not be included in this review.
Everolimus oral formulations are also available as Afinitor® and Afinitor Disperz® in different strengths for the treatment of various types of tumors. These formulations and indications will not be included in this review.

OVERVIEW

The ultimate goal of immunosuppressive therapy after organ transplantation is to prevent organ rejection, prolong graft and patient survival by providing an environment of permanent acceptance or tolerance where the new organ is recognized as “self” by the host’s immune system. The sequence of events in graft rejection is (1) recognition of donor’s histocompatibility differences by the recipient’s immune system, (2) recruitment of activated lymphocytes, (3) initiation of immune effector mechanisms, and (4) destruction of the graft. These events can take place at varying rates and may involve differing effects or mechanisms. Therefore, rejection of the transplanted tissue can take place at any time following surgery.

Rejection can be classified as hyperacute, acute cellular, or chronic. Hyperacute rejection may occur when donor-specific antibodies are present in the recipient at the time of transplant. It often occurs within minutes of transplant but may occur anytime within the first 2 weeks following surgery. Alloreactive T lymphocytes that appear in circulation infiltrate the allograft through the vascular endothelium and mediate acute cellular rejection. This type of rejection may occur as early as a few days postoperatively; however, it can occur any time after transplantation. The process of chronic rejection is poorly understood, although it may simply be a slow form of cellular rejection. The clinical presentation of chronic rejection is dependent on the organ grafted and generally presents as normal organ aging. The onset of chronic rejection is very slow, and the changes in organ function are not usually reversible.

The immunosuppressive drugs and dosing used in the maintenance of transplanted organs varies, but the regimens generally follow the same principles. Following induction therapy at the time of surgery, transplant recipients are started on drug regimens that consist of several categories. Using multiple agents capitalizes on the different immune-mediated mechanisms of action and may also allow for the use of lower doses of individual agents in order to minimize toxicity. Antiproliferative agents, such as azathioprine (Azasan, Imuran) and mycophenolate (CellCept, Myfortic), are used as adjunctive therapy. Sirolimus (Rapamune) and everolimus (Zortress) are proliferation inhibitors with mechanisms of action different from that of mycophenolate. They may be used to decrease the doses of calcineurin inhibitors (CNI), such as cyclosporine (Gengraf, Neoral, Sandimmune) or tacrolimus (Astagraf XL, Envarsus XR, Prograf), which are typically included in the regimen but can have serious adverse events at higher therapeutic concentrations.

The 2009 KDIGO (Kidney Disease Improving Global Outcomes) clinical practice guidelines for the care of kidney transplant recipients recommends using a combination of a CNI and an antiproliferative agent, with or without corticosteroids, as initial maintenance immunosuppressive therapy (1B). Further, these guidelines suggest tacrolimus be the first-line CNI used (2A) and that mycophenolate be the first-line antiproliferative agent (2B). The guidelines recommend that if a mammalian target of rapamycin (mTOR) inhibitor such as everolimus or sirolimus is utilized, it should not be started until graft function is established and surgical wounds are healed.

The American Association for the Study of Liver Diseases (AASLD) and the American Society of Transplantation have published guidelines for the long-term medical management of both adults and pediatric patients following liver transplantation. According to these guidelines, there is no
standard-of-care designation for choice of immunosuppressive regimen or particular dosing regimen. The choice of immunosuppressive regimen depends on a variety of factors including the indication for the transplantation and the risk of drug side effects.

The 2010 International Society of Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients state that calcineurin inhibitor-based therapy remains the standard in immunosuppressive protocols used after heart transplant (Class IIa, level of evidence [LOE] B). Notably, clinical data suggest that tacrolimus-based regimens may be associated with lower rejection rates but not with superior survival compared to cyclosporine (Class IIb, LOE B). In addition, mycophenolate mofetil, everolimus, or sirolimus (if tolerated) should be included in contemporary immunosuppressive regimens because these regimens have demonstrated a reduction in onset and progression of cardiac allograft vasculopathy (CAV) (Class IIa, LOE B). They recommend maintenance therapy with a CNI in all pediatric heart transplant recipients (Class I, LOE C), and further state that tacrolimus is preferred in those considered high immunologic risk (e.g., sensitized recipients with evidence of donor-specific antibody [DSA]) (Class IIa, LOE C). Most children should also receive adjunctive therapy with an anti-metabolite or a proliferation signal inhibitor (Class IIb, LOE C), and a mammalian target of rapamycin (mTOR) inhibitor should be considered in those with CAV (Class IIb, LOE C). Due to the various adverse effects, individualized therapy is emphasized. They state that initial therapy for antibody-mediated rejection (AMR) can include immunoadsorption and corticosteroids or plasmapheresis/low dose of intravenous immune globulin and corticosteroids. In addition, rituximab can be added to reduce the risk of recurrent rejection. Changes in therapy can be considered for maintenance immunosuppression in patients who experience AMR, and can include a switch to tacrolimus in patients receiving cyclosporine-based immunosuppression, increased doses of mycophenolate mofetil, and corticosteroids (all AMR recommendations Class IIa, LOE C). The ISHLT also provides detailed drug-specific guidance on monitoring of serum levels. Regarding the use of generic agents, in 2009, the ISHLT issued an Education Advisory recommending that clinicians should educate patients to discuss any changes in formulation or product appearance with their provider and that heightened vigilance is needed via closer therapeutic drug monitoring following changes in products.18

Azathioprine is indicated for the treatment of rheumatoid arthritis (RA), although is rarely used in this setting due to the more recent introduction of tumor necrosis factor inhibitors that are commonly employed in patients who fail to achieve an adequate response with disease-modifying antirheumatic drugs (DMARDs). According to the 2015 American College of Rheumatology guidelines, initial therapy for RA should include early use of a DMARD with methotrexate listed as the preferred initial therapy for most patients with early RA who have active disease.19 The guidelines state that azathioprine, cyclosporine, minocycline, and gold were considered by the reviewers but were not included in the guidelines for RA based on their infrequent use and lack of new data since 2012.

Cyclosporine has also been used for the treatment of severe, refractory plaque psoriasis in patients unresponsive to other therapies. The American Academy of Dermatology (AAD) recommends cyclosporine only be considered in adult, nonimmunocompromised patients with severe (extensive or disabling), recalcitrant psoriasis.20 Recalcitrant is further defined as those patients who have failed to respond to at least one systemic therapy or in patients for whom other systemic therapies are contraindicated or cannot be tolerated. The AAD acknowledges that some guidelines suggest the use of cyclosporine for moderate to severe psoriasis and state that cyclosporine efficacy has been observed for erythrodermic psoriasis, generalized pustular psoriasis and palmoplantar psoriasis.
Sirolimus (Rapamune) also carries FDA-approval for the treatment of lymphangioleiomyomatosis (LAM). LAM is a rare progressive lung disease of women that usually occurs during their childbearing years. LAM affects predominantly the lungs but also the kidneys and lymphatic system. Sirolimus is the first approved treatment that helps to stabilize lung function in some women with LAM. The American Thoracic Society/Japanese Respiratory Society clinical practice guidelines for LAM diagnosis and management recommend treating LAM patients who have abnormal/declining lung function with sirolimus (Rapamune) (strong recommendation, based on moderate-quality evidence). For selected patients with LAM with problematic chylous effusions, treatment with sirolimus is recommended before invasive management (conditional recommendation based on low-quality evidence). Sirolimus is the only recommended treatment for LAM in these guidelines and several other agents including doxycycline and hormonal treatment have specific recommendations against their use in LAM patients.

**PHARMACOLOGY**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Mechanism of Action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Calcineurin Inhibitors</strong></td>
<td></td>
</tr>
<tr>
<td>cyclosporine</td>
<td>Calcineurin inhibition results in impaired transcription of early activation of T-cells; through the inhibition of interleukin-2 (IL-2), cyclosporine specifically and reversibly inhibits immunocompetent lymphocytes in the G₀ and G₁ phase of the cell cycle, thus decreasing T-cell activation</td>
</tr>
<tr>
<td>tacrolimus</td>
<td>Calcium, calmodulin, and calcineurin are formed and the phosphatase activity of calcineurin is inhibited; this effect may prevent the dephosphorylation and translocation of activated T cells, a nuclear component thought to initiate gene transcription for the formation of lymphokines. Tacrolimus inhibits T lymphocyte activation possibly by binding to an intracellular protein, FKBP-12, forming a complex</td>
</tr>
<tr>
<td><strong>Antiproliferative Agents</strong></td>
<td></td>
</tr>
<tr>
<td>azathioprine</td>
<td>Azathioprine inhibits purine metabolism; inhibits the synthesis of DNA, RNA, and proteins; interferes with cellular metabolism; and inhibits mitosis. Azathioprine acts as a suppressor of delayed hypersensitivity and cellular cytotoxicity to a greater extent than it acts as a suppressor of antibody responses.</td>
</tr>
<tr>
<td>mycophenolate</td>
<td>Mycophenolate mofetil is a prodrug that is immediately and completely hydrolyzed to the active metabolite, mycophenolate (mycophenolic acid), a reversible and competitive inhibitor of inosine monophosphate dehydrogenase. It inhibits the de novo synthesis of the guanosine nucleotide without incorporation into DNA and exerts a potent cytostatic effect on B and T lymphocytes.</td>
</tr>
<tr>
<td><strong>mammalian Target of Rapamycin (mTOR) Inhibitors</strong></td>
<td></td>
</tr>
<tr>
<td>everolimus</td>
<td>Everolimus inhibits antigenic- and interleukin (IL-2 and IL-15)-stimulated activation and proliferation of T- and B-lymphocytes. In cells, everolimus binds to FKBP-12 to form an immunosuppressive complex that binds to and inhibits the mTOR, a key regulatory kinase. Consequently, subsequent protein synthesis and cell proliferation are inhibited. The everolimus:FKBP-12 complex has no effect on calcineurin activity.</td>
</tr>
<tr>
<td>sirolimus</td>
<td>Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine stimulation by a unique mechanism. Sirolimus also binds to FKBP-12 to generate an immunosuppressive complex that has no effect on calcineurin; this complex binds to and inhibits the activation of mTOR, resulting in suppression of cytokine-driven T cell proliferation and inhibition of the progression from the G₁ to the S phase of the cell cycle.</td>
</tr>
</tbody>
</table>
## PHARMACOKINETICS

<table>
<thead>
<tr>
<th>Drug</th>
<th>Half-life (hr)</th>
<th>Metabolites</th>
<th>Excretion (%)</th>
<th>Target Drug Concentrations</th>
</tr>
</thead>
<tbody>
<tr>
<td>azathioprine (Azasan, Imuran)</td>
<td>5</td>
<td>6-mercaptopurine 6-thioinosinic acid</td>
<td>Hepatic Renal (1–2)</td>
<td>Not measured</td>
</tr>
<tr>
<td>cyclosporine (Sandimmune)</td>
<td>19</td>
<td>--</td>
<td>Biliary Renal (6, 0.1 unchanged)</td>
<td>100–200 ng/mL (may vary depending on specific organ transplanted)</td>
</tr>
<tr>
<td>cyclosporine, modified (Gengraf, Neoral)</td>
<td>8.4</td>
<td>--</td>
<td>Biliary Renal (6, 0.1 unchanged)</td>
<td>100–200 ng/mL (may vary depending on specific organ transplanted)</td>
</tr>
<tr>
<td>everolimus (Zortress)</td>
<td>30</td>
<td>--</td>
<td>Fecal 80 Renal 5</td>
<td>3–8 ng/mL whole blood trough concentrations using LCMSMS</td>
</tr>
<tr>
<td>mycophenolate mofetil (CellCept)</td>
<td>17.9</td>
<td>mycophenolic acid MPA-O-glucuronide MPA-acyl glucuronide</td>
<td>Fecal 6 Renal 93</td>
<td>Not measured</td>
</tr>
<tr>
<td>mycophenolate sodium (Myfortic)</td>
<td>8–16</td>
<td>MPA-O-glucuronide MPA-acyl glucuronide</td>
<td>Renal &lt;60 (3 unchanged)</td>
<td>Not measured</td>
</tr>
<tr>
<td>sirolimus (Rapamune)</td>
<td>57–63         (up to 72 in males)</td>
<td>Hydroxysirolimus Demethylsirolimus hydroxy-demethylsirolimus</td>
<td>Fecal 91 Renal 2.2</td>
<td>Adult Pediatric</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>High immunologic risk:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10–15 ng/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>≥ 13 years old and</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt; 40 kg: 16-24 ng/mL for</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12 months, then</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12–20 ng/mL thereafter</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Low to moderate immunologic risk:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Following cyclosporine</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>withdrawal: 16–24 ng/mL for</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12 months, then</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12–20 ng/mL thereafter</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tacrolimus (Prograf)</td>
<td>11.3</td>
<td>13-demethyl tacrolimus di-demethyl-tacrolimus</td>
<td>Renal &lt;1 unchanged Bile extensive</td>
<td>Adult Pediatric</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Kidney transplant,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Month 1 to 3: 7–20 ng/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Month 4 to 12: 5–15 ng/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Liver transplant,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Month 1 to 12: 5–20 ng/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Liver transplant,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Month 1 to 12: 5–20 ng/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Heart transplant,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Month 1 to 3: 10–20 ng/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>≥ 4 months: 5–15 ng/mL</td>
</tr>
</tbody>
</table>
### Pharmacokinetics (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Half-life (hr)</th>
<th>Metabolites</th>
<th>Excretion (%)</th>
<th>Target Drug Concentrations</th>
</tr>
</thead>
<tbody>
<tr>
<td>tacrolimus extended-release (Astagraf XR)</td>
<td>32–48</td>
<td>13-demethyl tacrolimus, 31-demethyl tacrolimus</td>
<td>Fecal 93, Urine: 2</td>
<td>With basiliximab induction without induction Day 1–60: 5–17 ng/mL Month 3–12: 4–12 ng/mL Day 1–60: 6–20 ng/mL Month 3–12: 6–14 ng/mL</td>
</tr>
<tr>
<td>tacrolimus extended-release (Envarsus XR)</td>
<td>31 ± 8.1</td>
<td>13-demethyl tacrolimus, 31-demethyl tacrolimus</td>
<td>Fecal 93, Urine: 2</td>
<td>Whole blood trough concentration range of 4 to 11 ng/mL</td>
</tr>
</tbody>
</table>

Because the rate and extent of absorption of mycophenolate mofetil and mycophenolate sodium delayed-release products are not equal, these products should not be used interchangeably without health care provider (HCP) supervision.

Because the various cyclosporine products, including some nonproprietary products, are not bioequivalent to each other due to differences in the rate and extent of absorption, these products should not be used interchangeably without HCP supervision.

Tacrolimus extended-release capsules (Astagraf XL) are not interchangeable with tacrolimus immediate-release capsules or tacrolimus extended-release tablets (Envarsus XR).

Patients with malabsorption may have difficulty in achieving therapeutic cyclosporine levels with Sandimmune soft gelatin capsules or oral solution.

**CONTRAINDICATIONS/WARNINGS**

Azathioprine is contraindicated in the treatment of RA in pregnant women. All the drugs in this review are contraindicated in patients with known hypersensitivity to the specific drug or excipients used in the preparation.

All immunosuppressants in this category carry warnings, including boxed warnings, regarding the risk of development of serious infections, especially for transplant recipients. Fungal, viral, bacterial, and protozoal infections should be treated aggressively as infections may be fatal. Activation of latent viral infections should be monitored. Polyomavirus, especially BK virus, activation may result in serious and sometimes, fatal outcomes. Reduction of immunosuppressant dosage or use of other drugs should be considered as well. Immunosuppressant labeling also contains a boxed warning that only individuals well versed in the management of systemic immunosuppressive therapy who are capable of monitoring these agents appropriately should prescribe them. These agents may also increase the risk of lymphoma or other neoplasias, particularly those of the skin. Patients should be warned to avoid excess ultraviolet light exposure. The increased risk appears related to the intensity and duration of immunosuppression rather than to the use of specific agents.

The use of live vaccines should be avoided during treatment with any of the agents in this review.

The risk of developing neoplasia is increased dramatically in azathioprine-treated patients with RA who have received previously therapy with alkylating agents (cyclophosphamide, chlorambucil, melphalan, or others).

Azathioprine is metabolized to 6-mercaptopurine (6-MP) and then undergoes 2 major inactivation routes. One route is thiol methylation, which is catalyzed by the enzyme thiopurine S-methyltransferase (TPMT) to form an inactive metabolite. TPMT activity is controlled by a genetic
polymorphism. Approximately 10% of Caucasians and African Americans have 1 non-functional TPMT allele and 0.3% of this population has 2 TPMT non-functional alleles. Patients with 1 non-functional TPMT allele (intermediate TPMT activity) may be at increased risk of myelotoxicity at conventional doses of azathioprine. Patients with 2 non-functional TPMT alleles are at an increased risk of developing severe, life-threatening myelotoxicity when receiving conventional doses of azathioprine.

Likewise, 6-thioguanine nucleotides (6-TGNs) are major metabolites of the 6-MP activation process, and the nucleotide diphosphatase (NUDT15) enzyme is involved in conversion of the 6-thioguanine nucleotides (6-TGNs) to inactive 6-TG monophosphates. Genetic polymorphisms also influence NUDT15 activity; thus, patients with reduced NUDT15 activity also are at risk for severe myelosuppression. NUDT15 deficiency occurs in < 1% of patients of European or African ancestry, while approximately 2% of those of East Asian ancestry have 2 loss-of-function alleles and 21% have 1 loss-of-function allele. Evaluation for TPMT and NUDT15 should be considered in patients with severe myelosuppression. Alternative therapy should be considered in patients with homozygous TPMT or NUDT15 deficiency and reduced dosages in patients with heterozygous deficiency.

Cyclosporine products are contraindicated in psoriasis or RA patients with abnormal renal function, uncontrolled hypertension, or malignancies. Cyclosporine products are also contraindicated if given to psoriasis patients concomitantly with photochemotherapy (psoralen and ultraviolet A [PUVA] or ultraviolet B [UVB]), methotrexate, or other immunosuppressive agents, coal tar or radiation therapy due to the risk of fatal malignancies and/or infections.

Azathioprine (Azasan, Imuran) labeling contains an additional boxed warning regarding reports of post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease. Azathioprine may cause severe leukopenia, thrombocytopenia, macrocytic anemia, or severe bone marrow depression. These hematologic toxicities are dose-related and seem to be more severe in renal transplant patients who are undergoing organ rejection.

The boxed warnings for cyclosporine products reminds practitioners that the bioavailability of cyclosporine (Sandimmune) is not equal to that of cyclosporine; modified (Gengraf, Neoral) and appropriate monitoring should take place if a product change is necessary. Because the absorption of cyclosporine soft gelatin capsules and oral solution can be erratic, prescribers are also warned to monitor cyclosporine concentrations at repeated regular intervals to make sure therapeutic concentrations are maintained.

Cyclosporine products have the potential for thrombocytopenia and microangiopathic hemolytic anemia, hyperkalemia, hyperuricemia, hepatotoxicity, convulsions, encephalopathy, and anaphylaxis. Recommended doses of cyclosporine may cause systemic hypertension and nephrotoxicity. This risk increases as the dose and duration of therapy increases. Monitor renal function during therapy, as renal dysfunction, including structural kidney damage, is a potential adverse effect of cyclosporine. Since cyclosporine may cause hyperkalemia, potassium-sparing diuretics should not be used to treat hypertension.

Everolimus (Zortress) has a boxed warning for increased incidence of kidney graft thrombosis, and prescribers are cautioned to use reduced doses of cyclosporine in combination with everolimus to reduce nephrotoxicity. Use of everolimus in heart transplantation is not recommended due to increased mortality. Patients who have hypersensitivity reactions to sirolimus (Rapamune) should not take everolimus.
The use of everolimus and sirolimus have been associated with angioedema, impaired wound healing, fluid accumulation, hyperlipidemia, non-infectious pneumonitis, and proteinuria. New onset diabetes mellitus after transplantation and male infertility have also been reported with everolimus. The concomitant use of everolimus with cyclosporine may increase the risk of thrombotic microangiopathy/thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Monitor hematologic parameters. Everolimus should not be administered earlier than 30 days after liver transplant due to an associated increase in hepatic artery thrombosis reported with mammalian target of rapamycin (mTOR) inhibitors. Based on animal studies and their mechanisms of action, everolimus and sirolimus can cause fetal harm when administered to a pregnant woman.

Cases of interstitial lung disease (ILD), some reported with pulmonary hypertension, including pulmonary arterial hypertension, have occurred in patients receiving everolimus or sirolimus. Most cases generally resolve on drug interruption; however, fatal cases have occurred. A diagnosis of ILD should be considered in patients presenting with symptoms consistent with infectious pneumonia but not responding to antibiotic therapy and in whom infectious, neoplastic and other non-drug causes have been ruled-out through appropriate investigations.

Patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, which are rare hereditary disorders, should not take everolimus due to risk of diarrhea and malabsorption.

Mycophenolate (CellCept, Myfortic) labeling contains a boxed warning for an increased risk of first trimester pregnancy loss and congenital abnormalities if taken during pregnancy. Patient counseling and contraception is recommended for women of child bearing potential. If hormonal contraception is utilized (e.g., birth control pill, transdermal patch, vaginal ring, parenteral options), an additional barrier contraceptive method must be used due to the potential for mycophenolate to interfere with the metabolism of these agents.

Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolic acid (MPA) derivatives in combination with other immunosuppressive agents. Patients receiving mycophenolate may develop severe neutropenia [absolute neutrophil count (ANC) less than 0.5 × 10^3/mcL]. Patients should be monitored for blood dyscrasias and if they occur, therapy should be interrupted or the dose reduced, appropriate diagnostic tests performed, and the patient managed appropriately.

Cases of progressive multifocal leukoencephalopathy (PML), sometimes fatal, have been reported in patients treated with mycophenolate mofetil and mycophenolate sodium (MMF, MPA; CellCept, Myfortic), as well as azathioprine. Hemiparesis, apathy, confusion, cognitive deficiencies, and ataxia were the most frequent clinical features observed. PML may be due to activation of Polyomavirus (e.g., JC virus). The reported cases generally had risk factors for PML, including treatment with immunosuppressant therapies and impairment of immune functions. In immunosuppressed patients, physicians should consider PML in the differential diagnosis in patients reporting neurological symptoms taking mycophenolate mofetil or mycophenolate (CellCept, Myfortic) and consultation with a neurologist should be considered as clinically indicated.

Viral reactivations of hepatitis B (HBV) or hepatitis C (HCV) as well as cytomegalovirus (CMV) have been reported in patients treated with immunosuppressants, including mycophenolate. Consideration should be given to reducing immunosuppression in patients who develop evidence of new or reactivated viral infections. Other reported infections include polyomavirus-associated nephropathy (PVAN), especially due to BK virus infection.
Mycophenolate should be used with caution in patients with active serious digestive system disease. Gastrointestinal bleeding has been observed as well as rare cases of gastrointestinal perforation. The mycophenolate mofetil (Cellcept) oral suspension contains aspartame, a source of phenylalanine, and can be harmful in patients with phenylketonuria (PKU).

Mycophenolate is an (inosine monophosphate dehydrogenase (IMPDH) inhibitor and should be avoided in patients with rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndromes because exacerbated disease symptoms such as gout, tophi, nephrolithiasis or renal disease including renal failure due to the overproduction and accumulation of uric acid may occur.

Due to the risk of embryofetal toxicity, patients should not donate blood during mycophenolate therapy and for at least 6 weeks following discontinuation, as this could then be administered to a female of reproductive potential or pregnant woman. Similarly, men should not donate semen during therapy or for 90 days following discontinuation.

Sirolimus (Rapamune) carries a boxed warning advising that the safety and efficacy of sirolimus in liver and lung transplant patients have not been established; therefore, use is not recommended. In a study in de novo liver transplant patients, the combination of sirolimus and tacrolimus (Prograf) was associated with excess mortality and graft loss. Many of these patients had evidence of infection at or near the time of death. In this and another study in de novo liver transplant recipients, the use of sirolimus in combination with cyclosporine or tacrolimus was associated with an increased risk of hepatic artery thrombosis (HAT). Most cases of HAT occurred within 30 days post-transplantation and led to graft loss or death. When sirolimus has been used as part of an immunosuppressant regimen for lung transplant cases, bronchial anastomotic dehiscence, mostly fatal, has been reported.

Sirolimus must be protected from light. Like other mTOR inhibitors, it also carries a warning for embryofetal toxicity.

The safety and efficacy of sirolimus without concurrent cyclosporine treatment in renal transplant patients have not been adequately studied; therefore, it is not recommended.

The concomitant use of sirolimus and a CNI may increase the risk of CNI-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiography (HUS/TTP/TMA).

Tacrolimus (Astagraf XL, Envarsus XR, Prograf) may also cause insulin-dependent post-transplant diabetes mellitus in as many as 11% to 22% of transplant patients. Tacrolimus can also induce nephrotoxicity, which was reported in about 36% to 59% of transplantation patients. To avoid nephrotoxicity, cyclosporine, in particular, should not be used within 24 hours of tacrolimus. Approximately 55% of liver transplant patients developed neurotoxicity, including tremor and headache, and other changes in motor function, mental status, and sensory function in 2 randomized studies. Mild to severe hyperkalemia was reported in 8% to 45% of transplant recipients after treatment with tacrolimus.

Agranulocytosis and cases of pure red cell aplasia (PRCA) have also been reported in patients treated with tacrolimus. All patients reported risk factors for PRCA such as parvovirus B19 infection, underlying disease, or concomitant medications associated with PRCA. If PRCA is diagnosed, discontinuation of tacrolimus or tacrolimus extended-release (ER) should be considered.
Hypertension has been reported in patients treated with tacrolimus. Tacrolimus has been associated with myocardial hypertrophy, particularly in those with high drug trough concentrations. It is reversible in most cases following dose reduction or discontinuation.

Tacrolimus may prolong the QT/QTc interval and may cause torsade de pointes and should be avoided in patients with congenital long QT syndrome. Consideration for obtaining electrocardiograms and monitoring serum electrolytes should be given in patients with congestive heart failure, bradyarrhythmias or those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation as well as patients with hypokalemia, hypocalcemia, or hypomagnesemia.

Coadministration of tacrolimus (Astagraf XL, Envarsus XR, Prograf) with strong CYP3A4-inhibitors (list not inclusive: grapefruit juice, protease inhibitors, azole antifungals, verapamil, diltiazem, nifedipine, macrolide antibiotics, chloramphenicol) or strong CYP3A4-inducers (list not inclusive: rifampin, rifabutin, phenytoin, carbamazepine, phenobarbital, St. John’s wort) is not recommended without dosing adjustments of tacrolimus and close monitoring of tacrolimus whole blood trough concentrations and tacrolimus-associated adverse reactions. This is especially important with drugs that prolong the QT interval. In such cases monitoring for QT prolongation is also recommended.

Tacrolimus has been associated with gastrointestinal perforation; all reported cases have been considered to be a complication of transplant surgery or accompanied by infection, diverticulum, or malignant neoplasm.

An additional boxed warning for tacrolimus ER is the risk of increased mortality in female liver transplant recipients. A clinical trial involving 471 liver transplant patients randomized to either tacrolimus ER (Astagraf XL) or tacrolimus (Prograf) demonstrated a 10% higher mortality among the 76 female patients (18%) treated with tacrolimus ER (Astagraf XL) compared to the 64 female patients (8%) treated with tacrolimus at 12 months. Use of tacrolimus ER is not recommended in liver transplantation.

Tacrolimus also carries warnings for neurotoxicity and nephrotoxicity.

All of the warnings associated with tacrolimus are applicable to tacrolimus ER.

Tacrolimus ER (Astagraf XL) capsules are not interchangeable or substitutable with tacrolimus immediate-release capsules or tacrolimus ER (Envarsus XR) tablets. Likewise, tacrolimus (Prograf) is not considered interchangeable with other formulations. There have been reports of medication and dispensing errors during post-marketing surveillance. Cases of graft rejection have occurred that may have been related to the medication error and the resulting under- or over-exposure to tacrolimus.

Risk Evaluation and Mitigation Strategy (REMS)\textsuperscript{61}

Mycophenolate-containing products (CellCept, Myfortic) REMS requirement consists of a Medication Guide, elements to assure safe use, such as HCP training and communications, and assessments of the REMS. Patients must also be enrolled in a registry.

DRUG INTERACTIONS\textsuperscript{62,63,64,65,66,67,68,69,70,71,72,73,74}

Avoid the concomitant use of azathioprine (Azasan, Imuran) and mercaptopurine due to the potential for severe myelosuppression. Coadministration of azathioprine and any agent that may affect leukocyte production should be cautioned as this combination may lead to exaggerated leukopenia, especially in renal transplant patients. Anemia and severe leukopenia are also possible with
concomitant use of angiotensin-converting enzyme inhibitors (ACEIs) and azathioprine. Concomitant use of azathioprine with xanthine oxidase (XO) inhibitors (allopurinol or febuxostat) may lead to an increased plasma concentration of azathioprine or its metabolite. Concurrent use with allopurinol administration requires azathioprine dose reduction by 66% to 75%, and use with febuxostat is not recommended. Cases of severe pancytopenia have been reported in patients with hepatitis C who were receiving ribavirin in conjunction with azathioprine. Patients receiving this combination should have complete blood counts monitored weekly for the first month, twice monthly for the second and third months and then monthly thereafter. There is in vitro evidence that aminosalicylate derivatives (e.g., sulfasalazine, mesalazine) inhibit the TPMT enzyme and therefore the use of these agents with azathioprine is cautioned.

Azathioprine may inhibit the anticoagulant effect of warfarin.

Concomitant use of cyclosporine products (Gengraf, Neoral, Sandimmune) with other nephrotoxic drugs, including non-steroidal anti-inflammatory drugs (NSAIDs), may potentiate renal dysfunction, especially in dehydrated patients. Because cyclosporine is extensively eliminated by cytochrome P450 3A4 and P-glycoprotein (P-gp), monitoring of circulating cyclosporine concentrations and appropriate dosage adjustments are essential when used concomitantly with other drugs that are inducers or inhibitors of CYP3A4 or P-gp. Drugs that are known to increase cyclosporine concentrations include (list not all-inclusive): calcium channel blockers (diltiazem, nicardipine, verapamil), azole antifungals, macrolide antibiotics, quinupristin/dalfopristin, methylprednisolone, allopurinol, amiodarone, bromocriptine, colchicine, danazol, protease inhibitors, imatinib, metoclopramide, nefazodone and oral contraceptives. Grapefruit juice is also known to increase blood concentrations of cyclosporine. Drugs or dietary supplements known to decrease cyclosporine concentrations include (list not all-inclusive): rifampin, carbamazepine, phenobarbital, phenytoin, bosentan, octreotide, terbinafine, ticlopidine and St. John’s wort. In RA patients coadministered diclofenac or methotrexate with cyclosporine, the area under the curve (AUC) of diclofenac and methotrexate each was significantly increased. Orlistat decreases cyclosporine absorption and its use should be avoided in patients receiving oral cyclosporine. Frequent gingival hyperplasia has been reported with the concurrent administration of nifedipine and cyclosporine.

Potassium-sparing diuretics should not be used in conjunction with cyclosporine because hyperkalemia can occur. Caution is also advised when cyclosporine is coadministered with potassium-sparing drugs such as ACEIs and angiotensin II receptor antagonists (ARBs).

Cyclosporine itself is also an inhibitor of CYP3A4 and of P-gp, and therefore, may increase plasma concentrations of co-administered medications that are substrates for these metabolic pathways. Cyclosporine may decrease the clearance of (list not all-inclusive): digoxin, colchicine, ambrisentan, prednisolone, HMG-CoA reductase inhibitors (statins), aliskiren, repaglinide, NSAIDs, sirolimus, and etoposide. In patients receiving concomitant cyclosporine and sirolimus, sirolimus should be given 4 hours after cyclosporine administration to minimize increases in sirolimus blood concentrations.

Coadministration of dabigatran with cyclosporine should be avoided due to the potential for cyclosporine to result in increased dabigatran concentrations secondary to the P-gp inhibitory activity of cyclosporine.

CYP3A4 and P-gp are the primary elimination pathways of everolimus (Zortress), so concurrent therapy with moderate or strong inducers (e.g. ketoconazole, ritonavir, rifampin) or inhibitors (e.g. erythromycin) of CYP3As or P-gp may affect blood concentrations of everolimus. Verapamil, a
substrate of P-gp may increase exposure to everolimus and everolimus blood concentrations should be monitored when coadministered with verapamil. This includes cyclosporine, a 3A4 inhibitor with which everolimus may be administered, according to the indication. Everolimus itself may inhibit 3A4 and 2D6 enzymes. Coadministration of everolimus with depot octreotide has been shown to increase octreotide concentrations by 50%.

Mycophenolate products (CellCept, Myfortic) should not be given with azathioprine because these agents all work to inhibit purine metabolism and could potentially cause bone marrow suppression. Mycophenolate concentrations may be decreased by antacids containing magnesium or aluminum; therefore, do not administer concurrently.

Coadministration of PPIs (e.g., lansoprazole, pantoprazole) to patients receiving CellCept brand of mycophenolate has been reported to reduce mycophenolic acid (MPA) exposure by approximately 30% in patients; maximum concentration was decreased by 30% to 70%. This may possibly be due to decreased MPA solubility at an increased gastric pH. Although clinical relevance has not been established, PPIs should be used with caution when coadministered.

Mycophenolate is not recommended to be coadministered with cholestyramine or other agents that may interfere with enterohepatic recirculation including drugs that may alter the gastrointestinal flora such as ciprofloxacin. Cyclosporine also interrupts the enterohepatic recirculation of MPA, while tacrolimus does not interfere with this process. When MPA is administered concomitantly with cyclosporine or tacrolimus, patients should be monitored for MPA adverse events and have their dose of MPA reduced, if needed. **Drugs that interfere with glucuronidation may affect MPA systemic exposure.**

It is recommended that calcium free phosphate binders, such as sevelamer, are administered 2 hours after mycophenolate mofetil (CellCept) dose to minimize the impact on the absorption of MPA. A 67% reduction in MPA exposure was reported with concomitant administration of mycophenolate mofetil and rifampin; concurrent use is not recommended.

Rifampin should not be given concomitantly with MPA unless the benefit outweighs the risk of decreased exposure to MPA. The combination of metronidazole and norfloxacin reduced MPA exposure by one-third, and therefore, this combination is not recommended to be given concomitantly with MPA.

Patients with renal impairment who are receiving mycophenolate mofetil concurrently with acyclovir, ganciclovir or valganciclovir should be monitored closely for adverse reactions due to competition for tubular secretion which can increase the concentrations of both drugs.

Mycophenolate mofetil is not recommended to be administered with norfloxacin or metronidazole due to a reduction in mycophenolate concentrations.

Oral contraceptives should be used with caution in patients taking mycophenolate products and additional barrier contraceptive methods must be used.

Because sirolimus is known to be a substrate for cytochrome CYP3A4 and P-gp, coadministration of sirolimus with strong inhibitors (e.g. ketoconazole, voriconazole, clarithromycin) or inducers (e.g. rifampin, carbamazepine) of CYP3A4 and/or P-gp is not recommended. Grapefruit juice should be avoided in patients taking sirolimus. Use caution when combined with weak and moderate inducers or inhibitors of CYP3A4 and P-gp.
To prevent an additive or synergistic impairment of renal function, tacrolimus (Astagraf XL, Envarsus XR, Prograf) should be coadministered cautiously with other agents that may cause renal impairment, such as aminoglycosides, amphotericin B, and cisplatin. Tacrolimus is primarily metabolized by the CYP3A enzyme systems; therefore, substances known to inhibit these enzymes may decrease metabolism or increase bioavailability and drugs known to induce these enzyme systems may result in an increased metabolism or decreased bioavailability of tacrolimus. Coadministration of tacrolimus with strong CYP3A4-inhibitors (e.g., grapefruit juice, protease inhibitors, such as ritonavir, nelfinavir, telaprevir, and boceprevir, azole antifungals, calcium channel blockers, such as verapamil, diltiazem, nifedipine and nicardipine, macrolide antibiotics, chloramphenicol, cimetidine, amiodarone, bromocriptine, nefazodone, metoclopramide, danazol, ethinyl estradiol and methylprednisolone) or strong CYP3A4-inducers (e.g., rifampin, rifabutin, phenytoin, carbamazepine, phenobarbital, or St. John’s wort) is not recommended without dosing adjustments of tacrolimus and close monitoring of tacrolimus whole blood trough concentrations and tacrolimus-associated adverse reactions. This is especially important with drugs that prolong the QT interval, such as protease inhibitors and some antifungal agents. In such cases, monitoring for QT prolongation is also recommended. When voriconazole or posaconazole is initiated in patients already taking tacrolimus, the tacrolimus dose should be reduced to one-third of the original dose and subsequent dosing be based on monitoring of tacrolimus whole blood trough concentrations. Coadministration of magnesium and aluminum hydroxide antacids also increase tacrolimus concentrations and monitoring of tacrolimus whole blood concentrations are recommended when these agents are used concomitantly with tacrolimus.

Grapefruit juice should be avoided with tacrolimus due to the possibility of increased tacrolimus whole blood concentrations.

Lansoprazole and omeprazole may compete with tacrolimus for metabolism through the CYP3A4 system and may substantially increase tacrolimus whole blood concentrations.

Consumption of alcohol with tacrolimus ER (Astagraf XL, Envarsus XR) may increase the rate of release or alter the pharmacokinetic properties of tacrolimus, and therefore, alcoholic beverages should not be consumed with tacrolimus ER (Astagraf XL, Envarsus XR).

The use of live attenuated vaccines should be avoided when possible in patients receiving any oral immunosuppressant and vaccination may be less effective in patients receiving immunosuppressive therapy.
**ADVERSE EFFECTS**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Headache</th>
<th>Nausea</th>
<th>Vomiting</th>
<th>Diarrhea</th>
<th>Rash</th>
<th>Tremor</th>
<th>Liver toxicity</th>
<th>Other common effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>azathioprine (Azasan, Imuran)</td>
<td>nr</td>
<td>reported</td>
<td>reported</td>
<td>reported</td>
<td>reported</td>
<td>nr</td>
<td>reported</td>
<td>leukopenia, thrombocytopenia</td>
</tr>
<tr>
<td>cyclosporine* (Sandimmune)</td>
<td>2–15</td>
<td>2–10</td>
<td>2–10</td>
<td>3–8</td>
<td>nr</td>
<td>12–55</td>
<td>4–7</td>
<td>gum hyperplasia, hypertension, renal dysfunction, hirsutism</td>
</tr>
<tr>
<td>everolimus (Zortress)</td>
<td>18</td>
<td>29</td>
<td>15</td>
<td>19</td>
<td>1–10</td>
<td>8</td>
<td>1–10</td>
<td>constipation, peripheral edema, anemia, lipid abnormalities, delayed wound healing/fluid accumulation</td>
</tr>
<tr>
<td>mycophenolate mofetil (CellCept)</td>
<td>reported</td>
<td>19.9–54.5</td>
<td>32.9–33.9</td>
<td>31–51.3</td>
<td>22.1</td>
<td>24.2–33.9</td>
<td>24.9</td>
<td>leukopenia, anemia, infection</td>
</tr>
<tr>
<td>mycophenolate sodium (Myfortic)</td>
<td>3–20</td>
<td>24.5–29.1</td>
<td>23</td>
<td>21.4–23.5</td>
<td>3–20</td>
<td>3–20</td>
<td>nr</td>
<td>leukopenia, anemia, infection</td>
</tr>
<tr>
<td>sirolimus (Rapamune)</td>
<td>34</td>
<td>25–31</td>
<td>nr</td>
<td>25–35</td>
<td>10–20</td>
<td>nr</td>
<td>nr</td>
<td>peripheral edema, hypertension, lipid abnormalities, delayed wound healing/fluid accumulation</td>
</tr>
<tr>
<td>tacrolimus extended-release† (Astagraf XL)</td>
<td>12 (10)</td>
<td>15 (13)</td>
<td>13 (13)</td>
<td>27 (31)</td>
<td>nr</td>
<td>18 (17)</td>
<td>nr</td>
<td>new onset diabetes, infections, constipation</td>
</tr>
<tr>
<td>tacrolimus extended-release† (Envarsus XR)</td>
<td>9 (7)</td>
<td>nr</td>
<td>nr</td>
<td>14 (9)</td>
<td>nr</td>
<td>nr</td>
<td>nr</td>
<td>new onset diabetes, increased blood creatinine, infections nasopharyngitis, peripheral edema, hypertension</td>
</tr>
</tbody>
</table>

Adverse effects are reported as a percentage. Adverse effects data are obtained from package inserts and are not meant to be comparative or all inclusive. nr = not reported.

The adverse event data presented here indicates occurrence in transplant (renal, hepatic, cardiac) patients only.

* The package inserts for Gengraf and Neoral reference the adverse event data from studies using Sandimmune.

† The control arm for the Astagraf XL and the Envarsus XR studies were tacrolimus immediate-release (Prograf).

Pain in extremities, including Calcineurin Inhibitor Induced Pain Syndrome (CIPS), has been reported with calcineurin inhibitors.
SPECIAL POPULATIONS

Pediatrics

Safety and efficacy of azathioprine (Azasan, Imuran) and everolimus (Zortress) have not been established in the pediatric population.

Cyclosporine (Sandimmune) has been given to patients as young as 6 months of age without unusual adverse effects; however, there are no adequate, well-controlled studies in children. Cyclosporine, modified (Gengraf, Neoral) has been given to transplant recipients as young as 1 year of age without unusual adverse effects. Cyclosporine whole blood concentrations should be measured and dosages adjusted accordingly. The safety and efficacy of these products have not been established in children less than 18 years old with juvenile RA or psoriasis.

Safety and efficacy of mycophenolate mofetil (CellCept) have not been established in children receiving heart or liver transplants. Dosage in pediatric patients after renal transplantation is based on pharmacokinetic and safety data. Mycophenolate sodium (Myfortic) has established safety and efficacy in patients 5 to 16 years old who are at least 6 months post kidney transplant. Pediatric doses for patients with a body surface area (BSA) less than 1.19 m² cannot be accurately administered using the currently available formulations of mycophenolate sodium (Myfortic) tablets.

Safety and efficacy of sirolimus (Rapamune) for prophylaxis of organ rejection in renal transplantation have not been established in children younger than 13 years of age or in children younger than 18 who are considered to be at high immunologic risk. Safety and efficacy of sirolimus (Rapamune) in lymphangioleiomyomatosis patients less than 18 years have not been established.

Tacrolimus (Prograf) is approved for use in pediatric kidney, liver, or heart transplant patients. Pediatric liver transplant patients generally required higher doses of tacrolimus to maintain blood trough concentrations of tacrolimus similar to adult patients.

The safety and effectiveness of tacrolimus ER (Astagraf XL) have been established in pediatric kidney transplant patients with basiliximab induction, based on adequate and well-controlled studies in adult kidney transplant patients as well as pharmacokinetic and safety data in pediatric patients ≥ 4 years of age and able to swallow intact capsules.

The safety and efficacy of tacrolimus ER (Astagraf XL, Envarsus XR) in pediatric kidney transplant patients less than 16 years of age has not been established.

Pregnancy

Azathioprine can cause fetal harm when administered to pregnant women; therefore, azathioprine has been labeled Pregnancy Category D.

Mycophenolate (Myfortic) is Pregnancy Category D. Previously, mycophenolate (Cellcept) was Pregnancy Category D, but is labeling was updated and replaced with descriptive text in compliance with the Pregnancy and Lactation Labeling Rule (PLLR). While there are no adequate, well-controlled studies in pregnant women, the use of mycophenolate is associated with an increased risk of first trimester miscarriage and congenital malformations such as external ear and facial abnormalities and anomalies of the distal limbs, heart, esophagus, kidney and nervous system. Females of reproductive potential receiving mycophenolate products should be counseled regarding acceptable contraception. If hormonal contraception is utilized (e.g., birth control pill, transdermal patch, vaginal ring, parenteral
options), an additional barrier contraceptive method must be used due to the potential for mycophenolate to interfere with the metabolism of these agents. Pregnancy status should be assessed, when appropriate, prior to treatment initiation, and follow-up testing 8 to 10 days later and during routine follow-up visits is also recommended. If pregnancy is detected, an alternative immunosuppressant with a lower risk of embryofetal toxicity should be used when possible. Additional contraceptive recommendations for males and females are detailed in product labeling.

Cyclosporine products and sirolimus (Rapamune) are labeled Pregnancy Category C. Previously, everolimus (Zortress), tacrolimus (Prograf), and tacrolimus extended-release (Astagraf XL, Envarsus XR) were Pregnancy Category C, but this was replaced with descriptive text in compliance with the PLLR.

Based on animal studies and its mechanism of action, everolimus can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should avoid becoming pregnant and use effective contraception during treatment and for 8 weeks after ending treatment. Sirolimus may also cause embryofetal toxicity for these reasons. Females of reproductive potential should avoid becoming pregnant and use effective contraception during treatment with sirolimus and for 12 weeks after ending treatment.

Tacrolimus is transferred across the placenta and the use of tacrolimus during human pregnancy has been associated with risk of prematurity, birth defects/congenital anomalies, low birth weight, and fetal distress. It has also been associated with neonatal hyperkalemia and renal dysfunction.

**Renal Impairment**

The dose of azathioprine should be decreased for moderate to severe renal failure.

Patients with renal impairment should receive doses of tacrolimus at the lowest value of the recommended initial dosing range and renal function should be monitored. Doses of everolimus (Zortress) in patients with moderate or severe renal impairment should be reduced by one half initially.

In kidney transplant patients with severe chronic renal impairment should generally avoid mycophenolate (Cellcept) doses > 1 g administered twice daily. No data are available in heart or liver transplant patients.

**Hepatic Impairment**

No dose adjustments are required in kidney transplant patients using mycophenolate. No data are available in heart or liver transplant patients.

Cyclosporine is extensively metabolized by the liver. Patients with severe hepatic impairment may require reduced dosages of cyclosporine.

Patients taking everolimus who have moderate hepatic impairment should decrease the everolimus dose by half. There is no information available for patients with severe hepatic impairment.

For patients with mild or moderate liver impairment, it is recommended that the maintenance dosage of sirolimus be reduced by approximately one-third, and the maintenance dose should be reduced by one-half in those with severe liver impairment. However, it is not necessary to reduce the loading dose of sirolimus.

Due to greater whole blood trough concentrations, tacrolimus dosage reduction is recommended for patients with severe hepatic impairment. Patients with moderate hepatic impairment should have
their tacrolimus whole blood concentrations monitored. In patients with mild hepatic impairment, no dosage adjustments of tacrolimus are needed.

**Race**

The data in kidney transplant patients indicate that African American patients required a higher dose of tacrolimus (Prograf) and tacrolimus ER (Astagraf XL, Envarsus XR) to attain comparable trough concentrations compared to Caucasian patients. In addition, African American and Hispanic kidney transplant recipients who are taking tacrolimus are at an increased risk of new onset diabetes after transplantation.

**DOSAGES**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Initial Dose</th>
<th>Maintenance Dose</th>
<th>Pediatric Dose</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>azathioprine (Azasan, Imuran)</td>
<td>Transplant: 3–5 mg/kg once daily RA: 1 mg/kg/day (50–100 mg) once or twice daily</td>
<td>Transplant: 1–3 mg/kg once daily RA: 1–2.5 mg/kg/day once or twice daily</td>
<td>--</td>
<td>75 mg, 100 mg tablets (Azasan) 50 mg tablet (Imuran)</td>
</tr>
<tr>
<td>cyclosporine (Sandimmune)</td>
<td>15 mg/kg as a single dose 4 to 12 hours prior to transplant 14–18 mg/kg once daily for 1 to 2 weeks</td>
<td>Transplant: 5–10 mg/kg/day once daily; monitor whole blood trough levels with approximate range of 100–200 ng/mL</td>
<td>Same as adult, may require higher doses</td>
<td>100 mg/mL oral solution 25 mg, 100 mg soft gelatin capsules</td>
</tr>
<tr>
<td>cyclosporine, modified (Gengraf, Neoral)</td>
<td>Transplant: 15 mg/kg divided twice daily 4 to 12 hours prior to or immediately post-transplant</td>
<td>Transplant: 5–10 mg/kg/day; divided twice daily, monitor whole blood trough levels with approximate range of 100–200 ng/mL</td>
<td>Same as adult</td>
<td>Gengraf: 25 mg, 50 mg (generic only), 100 mg capsules Neoral: 25 mg, 100 mg soft gelatin capsules</td>
</tr>
<tr>
<td></td>
<td>Psoriasis / RA: 2.5 mg/kg divided twice daily</td>
<td>Psoriasis / RA: 2.5–4 mg/kg divided twice daily</td>
<td>--</td>
<td>100 mg/mL oral solution</td>
</tr>
<tr>
<td>everolimus (Zortress)</td>
<td>Kidney: 0.75 mg twice daily at the same time as cyclosporine Liver: 1 mg twice daily started at least 30 days post-transplant at same time as tacrolimus</td>
<td>Adjusted to maintain a trough whole blood concentration of 3–8 ng/mL using an LCMSMS assay</td>
<td>--</td>
<td>0.25 mg, 0.5 mg, 0.75 mg, 1 mg tablets</td>
</tr>
</tbody>
</table>
### Dosages (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Initial Dose</th>
<th>Maintenance Dose</th>
<th>Pediatric Dose</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>mycophenolate mofetil (CellCept)</td>
<td>--</td>
<td>Renal transplant: 1 gram twice daily</td>
<td>Renal transplant: 600 mg/m² twice daily (maximum 1 gram twice daily)</td>
<td>200 mg/mL powder for oral suspension</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cardiac transplant: 1.5 grams twice daily</td>
<td></td>
<td>250 mg capsule 500 mg tablet</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hepatic transplant: 1.5 grams twice daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mycophenolate sodium (Myfortic)</td>
<td>--</td>
<td>720 mg twice daily (empty stomach)</td>
<td>&gt;5 years of age who are at least 6 months post kidney transplant: 400 mg/m² twice daily (maximum 720 mg twice daily)</td>
<td>180 mg, 360 mg delayed release tablets</td>
</tr>
<tr>
<td>sirolimus (Rapamune)</td>
<td>High immunologic risk: Up to 15 mg loading dose on day 1; then 5 mg daily in combination with cyclosporine and corticosteroids for at least 12 months post transplantation</td>
<td>High immunologic risk: Adjust to a trough concentration of 10–15 ng/mL</td>
<td></td>
<td>0.5 mg, 1 mg, 2 mg tablets</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Low to moderate immunologic risk: 6 mg on day 1; then 2 mg daily in combination with cyclosporine and corticosteroids for 2 to 4 months post transplantation</td>
<td>Low to moderate immunologic risk: Following cyclosporine withdrawal, adjust to trough concentration of 16–24 ng/mL for 12 months then 12–20 ng/mL thereafter</td>
<td>1 mg/mL oral solution</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>≥ 13 years old and &gt; 40 kg: Same as adult</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adjust to trough level of 16–24 ng/mL for 12 months after cyclosporine withdrawal, then 12–20 ng/mL thereafter</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>≥ 13 years old and &lt; 40 kg: 3 mg/m² x 1 then 1 mg/m²/day</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Adjust to trough level of 16–24 ng/mL for 12 months then 12–20 ng/mL thereafter</td>
<td></td>
</tr>
<tr>
<td>Lymphangioleiomyomatosis: initially 2 mg/day</td>
<td></td>
<td>Measure whole blood trough concentrations in 10–20 days with dosage adjustment to maintain concentration between 5–15 ng/mL</td>
<td></td>
<td>--</td>
</tr>
</tbody>
</table>
## Dosages (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Initial Dose</th>
<th>Maintenance Dose</th>
<th>Pediatric Dose</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>tacrolimus (Prograf)</td>
<td>Kidney transplant: 0.2 mg/kg/day divided twice daily (in combination with azathioprine)</td>
<td>Kidney transplant in combination with azathioprine: Month 1 to 3: dose to a trough concentration of 7–20 ng/mL Month 4 to 12: dose to a trough concentration of 5–15 ng/mL Kidney transplant in combination with MPA month 1–12 dose to a trough concentration of 4–11 ng/mL</td>
<td>Kidney transplant: 0.3 mg/kg/day as capsules or suspension divided twice daily, every 12 hours</td>
<td>0.5 mg, 1 mg, 5 mg capsules 0.2 mg, 1 mg unit-dose packets containing granules for suspension*</td>
</tr>
<tr>
<td></td>
<td>0.1 mg/kg/day (in combinations with MPA)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver transplant:</td>
<td>0.1–0.15 mg/kg/day divided twice daily</td>
<td>Liver transplant: Month 1–12: dose to a trough concentration of 5–20 ng/mL</td>
<td>Liver transplant: 0.15–0.2 mg/kg/day capsules or 0.2 mg/kg/day suspension divided twice daily, every 12 hours</td>
<td>Kidney, heart, or liver transplant: Month 1 to 12: Dose to a trough concentration of 5–20 ng/mL</td>
</tr>
<tr>
<td>Heart transplant:</td>
<td>0.075 mg/kg/day divided twice daily</td>
<td>Heart transplant: Month 1 to 3: Dose to a trough concentration of 10–20 ng/mL Month 4: Dose to a trough concentration of 5–15 ng/mL</td>
<td>Heart transplant: 0.15–0.2 mg/kg/day as capsules or suspension divided twice daily</td>
<td></td>
</tr>
</tbody>
</table>

* A 1:1 conversion is recommended between formulations, but therapeutic drug monitoring is recommended. Detailed preparation and administration recommendations are outlined in the product labeling.
### Dosages (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Initial Dose</th>
<th>Maintenance Dose</th>
<th>Pediatric Dose</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>tacrolimus extended-release (Astagraf XL)</td>
<td>With basiliximab induction: 0.15 to 0.2 mg/kg/day prior to reperfusion or within 48 hours of complement of transplant procedure</td>
<td>During month 1: dose trough concentrations to 7 to 15 ng/mL; Months 2 to 6: dose to 5 to 15 ng/mL; &gt; 6 months: dose to 5 to 10 ng/mL</td>
<td>With basiliximab, mycophenolate mofetil, and steroids; Initial dose: 0.3 mg/kg once daily; administered within 24 hours following reperfusion</td>
<td>0.5 mg, 1 mg, 5 mg extended-release capsules</td>
</tr>
<tr>
<td>tacrolimus, extended release (Envarsus XR)</td>
<td>Conversion from immediate-release (IR) tacrolimus: give 80% of the total daily dose of the tacrolimus IR product</td>
<td>Conversion from immediate-release (IR) tacrolimus: adjust dose to achieve target whole blood trough concentration ranges of 4–11 ng/mL</td>
<td>De novo kidney transplant: initial dose of 0.14 mg/kg/day, titrating to target tacrolimus whole blood trough concentration of 6–11 ng/mL during month 1</td>
<td>0.75 mg, 1 mg, 4 mg extended-release tablets</td>
</tr>
</tbody>
</table>

Many immunosuppressive protocols require combinations of immunosuppressants with or without the addition of corticosteroids; please refer to product labeling for recommended combination regimens.

Do not crush, chew, or cut everolimus (Zortress), mycophenolate (CellCept, Myfortic), or sirolimus (Rapamune) tablets. Do not open mycophenolate (CellCept) capsules.

Tacrolimus extended-release (Astagraf XL, Envarsus XR) should be taken consistently every day around the same time, preferably in the morning. It should not be crushed, chewed, or cut. Patients should avoid eating grapefruit or drinking grapefruit juice or alcohol. Tacrolimus (Prograf) should be taken consistently with or without food.

TPMT phenotype testing is recommended for patients receiving azathioprine.

Cyclosporine (Sandimmune) solution can be made more palatable by diluting it with milk, chocolate milk, or orange juice at room temperature. Cyclosporine (Gengraf, Neoral) solution can be made more palatable by diluting it with apple juice or orange juice at room temperature.
Sirolimus (Rapamune) oral solution at a dose of 2 mg has been demonstrated to be clinically equivalent to sirolimus (Rapamune) tablets 2 mg; however, it is not known if higher doses of sirolimus oral solution are clinically equivalent on a mg-to-mg basis with sirolimus (Rapamune) tablets. Sirolimus (Rapamune) oral solution must be protected from light and the dose should be mixed with at least 2 ounces of water or orange juice in a glass or plastic container and stirred vigorously prior to administration.

**CLINICAL TRIALS**

**Search Strategy**

Articles were identified through searches performed on PubMed and review of information sent by the manufacturers. The search strategy included the FDA-approved use of all drugs in this class. Randomized, controlled, comparative trials are considered the most relevant in this category. Studies included for analysis in the review were published in English, performed with human participants, and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question and include follow-up (endpoint assessment) of at least 80% of participants entering the investigation. Despite some inherent bias found in all studies, including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship/funding must be considered, the studies in this review have also been evaluated for validity and importance.

Due to the large number of studies identified for the immunosuppressants, this review focuses on head-to-head trials meant to determine safety or efficacy for FDA-approved indications only. This review is not meant to encompass all trials involving the use of immunosuppressants, such as the benefit of steroid-free regimens, the timing of initiating calcineurin inhibitors or possible calcineurin inhibitor-sparing regimens. Many of the trials performed with these agents are open-label trials due to the need for therapeutic concentration monitoring.

**Cardiac Transplant**

**cyclosporine (Sandimmune) versus tacrolimus (Prograf)**

A single-center, randomized, prospective, open-label study was conducted to investigate whether trough concentration-adjusted mycophenolate mofetil is more efficacious in combination with tacrolimus or cyclosporine and to investigate the impact of either drug on mycophenolate mofetil dosage. Immunosuppressive therapy consisted of tacrolimus (n=30) dosed to a target blood trough concentration of 10 to 15 ng/mL or cyclosporine (n=30) dosed to a target blood trough concentration of 100 to 300 ng/mL in combination with mycophenolate mofetil dosed to a target blood trough concentration of 1.5 to 4 mg/mL and corticosteroids. Investigators tracked acute rejection episodes (ARE), survival data, and adverse events. No difference was seen between the groups in baseline characteristics. Corticosteroids were withdrawn within 6 months of cardiac transplant in all patients. The tacrolimus-treated patients had a lower incidence of ARE per 100 patient days compared to cyclosporine (0.03 versus 0.15; p=0.00007). However, overall patient survival during follow-up was similar (93% versus 90%) between the groups. Participants in the tacrolimus group required a lower
mycophenolate mofetil dose to achieve the targeted blood concentrations. After 2 years, the mean graft vessel disease score was 1.85 ± 3.18 in the tacrolimus group versus 3.95 ± 4.8 in the cyclosporine group (p=0.08). A 10-year follow-up of this group of patients was published in 2013. Survival for the tacrolimus plus mycophenolate mofetil (TAC/MMF) group was 96.7% at 1 year, 80% at 5 years and 66.7% at 10 years. Survival in the cyclosporine plus mycophenolate mofetil group (CsA/MMF) was 90% at 1 year, 88.3% at 5 years, and 80% at 10 years, none of these differences were statistically significant. Freedom from acute rejection episodes (ARE) was significantly higher in the TAC/MMF group (65.5%) versus the CsA/MMF group (21.7%; p=0.004). Freedom from cardiac allograft vasculopathy (CAV) after 5 and 10 years was 64% and 45.8% in the in the TAC/MMF group compared to 36% (p=0.085) and 8% (p=0.003) in the CsA/MMF group. There were no differences between the groups with regard to coronary angioplasty or stenting, renal dysfunction, diabetes mellitus, CMV infections, or malignancies.

The efficacy and safety of tacrolimus and cyclosporine were compared using 73 adult heart transplant patients in a single-center, prospective, randomized, open-label clinical trial. At the time of transplantation, patients were randomly assigned to receive either tacrolimus (n=43) or cyclosporine (n=30). Ten tacrolimus-treated patients received the drug intravenously in the perioperative period, and all other patients received oral tacrolimus only. The mean follow-up was 27 months. The 2 groups had similar patient survival rates (tacrolimus 83%, cyclosporine 81%). Fewer tacrolimus-treated patients (79%) experienced acute rejection when compared to cyclosporine-treated patients (100%, p=NS). The 2 groups were also similar with regard to the number of infections, rate of dialysis, and insulin requirements; however, the proportion of patients requiring multiple antihypertensives was lower in the tacrolimus group (12.5% versus 50% at month 6; p=0.025).

Patients were randomized in a 2:1 fashion to either oral tacrolimus (n=54) or cyclosporine (n=28). The 2 groups had similar rejection and survival rates at 1 year. Kaplan-Meier estimates showed a freedom from rejection of 26.3% for the tacrolimus-treated participants and 18.5% for the cyclosporine-treated participants (p=0.444). Survival rates were 79.6% in the tacrolimus arm and 92.9% in the cyclosporine arm (p=0.125). At 3 of the 5 centers, patients were treated with antithymocyte globulin during the immediate postoperative period. Acute rejection-free rates were 49.2% and 26.7% for tacrolimus and cyclosporine, respectively (p=0.08); for those treated with thymoglobulin, rejection-free rates were 7.1% and 8.3% (p=0.965). Patient survival rates were 84.6% and 93.3% (p=0.382) versus 75% and 92.3% (p=0.243). No significant differences were found between the groups in the overall rates of infection, impaired renal function (31.5% versus 21.4%), or glucose intolerance (7% versus 4.3%). Fewer patients receiving tacrolimus needed antihypertensive therapy (59.5% versus 87.5%; p=0.025).

Cardiac transplant recipients (n=95) were randomized at a single center to either open-label cyclosporine or tacrolimus and were followed to determine the rate of cytomegalovirus (CMV) infection in each group. All patients at highest risk of developing CMV (CMV recipients receiving CMV positive organs) received valganciclovir prophylaxis. CMV infection was considered as the detection of an increased viral load and/or the presence of CMV in histological samples, regardless of clinical symptoms. The rate of CMV infection overall (not just in highest risk patients) was higher in patients treated with cyclosporine than in those treated with tacrolimus (45.1% versus 15.9%; p=0.002). The group of patients treated with cyclosporine had a shorter mean survival time free from CMV infection than patients treated with tacrolimus (900 days versus 1,440 days; p=0.001).

The incidence of obesity in cardiac transplant recipients was studied in 101 heart transplant recipients who were randomly assigned to either cyclosporine or tacrolimus. At baseline there was no
difference in weight between the 2 groups. Obesity was defined as a body mass index of ≥ 25 m². One year after heart transplant, the mean weight gain was 6.9 ± 11 kg in the cyclosporine group compared to a weight loss of 0.03 ± 14 kg in the tacrolimus group (p=0.008). Multivariate analysis revealed that only cyclosporine treatment was an independent predictor of obesity 1 year after heart transplant (odds ratio [OR], 3.84; 95% CI, 1.04 to 14.21; p=0.01).

**cyclosporine, modified (Gengraf/Neoral) versus tacrolimus (Prograf)**

Tacrolimus (n=157) was compared to cyclosporine, modified (n=157), each in combination with azathioprine and corticosteroids, in a randomized controlled clinical trial of newly transplanted heart recipients. Acute rejection episodes were assessed by protocol biopsies, which underwent local and blinded central evaluation. At 18 months, patient and graft survival was 92.9% in the tacrolimus-treated group compared to 89.8% in the cyclosporine-treated group. The incidence of first biopsy-proven acute rejection of grade ≥ 1B at month 6, the primary end point, was 54% in the tacrolimus arm versus 66.4% in the cyclosporine arm (p=0.029). The incidence of first biopsy-proven acute rejection of grade ≥ 3A at month 6 was 28% in the tacrolimus group and 42% in the cyclosporine group (p=0.013). Significant differences (p≤0.05) were seen between the groups for adverse events, such as new-onset diabetes mellitus (20.3% versus 10.5%), post-transplant arterial hypertension (65.7% versus 77.7%), and dyslipidemia (28.7% versus 40.1%) for tacrolimus versus cyclosporine, respectively.

Heart transplant patients were randomized to receive either tacrolimus (n=33) or cyclosporine, modified (n=34), each in combination with corticosteroids and azathioprine, without induction, in a 5-year follow-up study. Endpoints included survival, Grade ≥ 3A or treated rejection, angiographic cardiac allograft vasculopathy, renal dysfunction, use of 2 or more antihypertensive medications, incidence of diabetes, and lipid concentrations. Significant differences were seen only for the tacrolimus-treated arm: lower 5-year mean triglyceride concentrations (97 ± 34 versus 172 ± 103 mg/dL; p=0.011) and average serum creatinine concentrations (1.2 ± 0.5 mg/dL versus 1.5 ± 0.4 mg/dL; p=0.044). The tacrolimus-treated arm showed a trend toward fewer patients requiring 2 or more antihypertensive drugs; however, this did not reach statistical significance.

A prospective, open-label, multicenter, 12-month study randomized 85 cardiac transplant recipients to receive either tacrolimus-based (n=39) or cyclosporine-based (n=46) immunosuppression. Fifteen patients (18%) were given peri-operative muromonab (Orthoclone, OKT3) due to pre-transplant renal dysfunction, to delay treatment with tacrolimus or cyclosporine. All patients received a triple-drug protocol with identical adjunctive immunosuppressant agents. Endomyocardial biopsies were performed at weeks 1, 2, 3, 4, 6, 8, 10, 12, 24, and 52. Patients were mostly male (87%), Caucasian (90%), had a mean age of 54 years, and primary diagnoses of coronary artery disease (55%), and idiopathic dilated cardiomyopathy (41%). Patient and allograft survival were not different between the treatment groups. Probability and overall incidence of each grade of rejection, whether treated or not, and the types of treatment required did not differ between the groups. At baseline and through 12 months of follow-up, serum cholesterol concentrations were higher in the cyclosporine group at 3, 6, and 12 months (239 versus 205 mg/dL, 246 versus 191 mg/dL, 212 versus 186 mg/dL, respectively; p≤0.001). No significant differences were seen in renal function, hyperglycemia, hypomagnesemia, or hyperkalemia during the first 12 months. More cyclosporine-treated patients developed new-onset hypertension requiring drug therapy (71% versus 48%; p=0.05). The incidence of infection was similar for the 2 groups.
mycophenolate mofetil versus azathioprine

A double blind, multicenter trial randomized 650 heart transplant patients to receive mycophenolate mofetil (MMF) 3,000 mg/day or azathioprine 1.5-3 mg/kg/day, in addition to cyclosporine and corticosteroids.\textsuperscript{123} Endpoints included incidence of rejection assessed at 6 months and survival at 12 months post-transplant. There was a significant reduction in mortality at 1 year favoring MMF treated patients (18 deaths; 6.2%) compared with azathioprine treated patients (33 deaths; 11.4%; \(p=0.031\)). There was also a significant reduction in the requirement for treatment of rejection in the MMF treated patients (65.7% versus 73.7%; \(p=0.026\)). MMF treated patients experienced a higher rate of opportunistic infections, mostly herpes simplex, compared to azathioprine-treated patients (53.3% versus 43.6%; \(p=0.025\)). A 3-year follow up of this study indicated 18.3% of azathioprine-treated patients had died or received another transplant at 36 months compared with 11.8% of MMF-treated patients (\(p<0.01\)).\textsuperscript{124} Congestive heart failure, atrial arrhythmias, and leukopenia were more common in the azathioprine group, while MMF-treated patients experienced a higher incidence of diarrhea, esophagitis, and viral infections.

Hepatic Transplant

cyclosporine versus tacrolimus (Prograf)

An open-label, multicenter trial randomized 478 adults and 51 children (\(\leq 12\) years of age) to receive tacrolimus (\(n=263\)) or cyclosporine (\(n=266\)) following hepatic transplantation.\textsuperscript{125} Participants were followed for 1-year post-transplant, with primary endpoints of 1-year patient and graft survival. The secondary endpoints were the incidence of acute rejection, corticosteroid-resistant rejection, and refractory rejection, defined as continued rejection after 2 courses of corticosteroids and an intravenous course of muromonab. A Kaplan-Meier analysis showed patient-survival rates at day 360 of 88% for both the tacrolimus and cyclosporine groups (\(p=0.85\)), and graft-survival rates of 82% and 79%, respectively (\(p=0.55\)). One hundred fifty-four patients in the tacrolimus arm and 173 patients in the cyclosporine arm experienced acute rejection (\(p\leq0.002\)), and 43 patients in the tacrolimus arm and 82 patients in the cyclosporine arm experienced corticosteroid-resistant rejection (\(p\leq0.001\)). In addition, refractory rejection occurred in 6 and 32 patients, respectively (\(p\leq0.001\)). Thirty-seven patients in the tacrolimus arm and 13 patients in the cyclosporine arm discontinued the study due to adverse events, primarily nephrotoxicity and neurotoxicity (\(p\leq0.001\)).

A total of 529 liver transplant patients participated in a one-year, randomized, multicenter study with a 4-year follow-up extension that compared the safety and efficacy of tacrolimus (\(n=263\)) to cyclosporine (\(n=266\)).\textsuperscript{126} Participants were evaluated at 3-month intervals to determine patient and graft survival rates, incidence of adverse events, and changes in laboratory and clinical profiles. Overall, patient and graft survival rates were comparable between the 2 groups (tacrolimus 79% and 71.8%; cyclosporine 73.1% and 66.4%, respectively). Hepatitis C-positive patients had improved survival with tacrolimus (78.9% tacrolimus group versus 60.5% cyclosporine group; \(p=0.041\)). The 2 groups had comparable incidences of late acute rejection, late steroid-resistant rejection and death or graft loss related to rejection. The safety profiles of both treatments were comparable.

The Randomized Evaluation of Fibrosis (REFINE) study was an open-label prospective, randomized, multicenter study.\textsuperscript{127} Adult patients (\(n=356\)) who had received a liver transplant for hepatitis C virus (HCV) cirrhosis were randomized to cyclosporine or tacrolimus-based regimens. Patients then entered a 12-month treatment phase, with a follow-up assessment at 24 months post transplant. The primary
endpoint was the rate of fibrosis stage ≥ 2 using Ishak-Knodell scoring by 12 months after liver transplantation. A total of 71.6% of patients randomized to cyclosporine, compared to 67.5% of patients randomized to tacrolimus had fibrosis score ≥ 2 at month 12 (OR, 1.11; 95% CI, 0.56 to 2.21; p=0.759). Similarly, no significant between-group difference occurred at month 24 (OR, 1.15; 95% CI, 0.47 to 2.8; p=0.767) in these patients. However, in the subset of patients who did not receive corticosteroids, a fibrosis score ≥ 2 was significantly less frequent with cyclosporine versus tacrolimus at month 12 (18.9% versus 42.1%; p=0.029).

cyclosporine, modified (Gengraf/Neoral) versus tacrolimus (Prograf)

A prospective, randomized, intent-to-treat, 4-year follow-up trial comparing cyclosporine, modified (n=50) to tacrolimus (n=49) was conducted to evaluate a multidrug approach that would reduce both early and long-term morbidity related to immunosuppression post-hepatic transplant without compromising efficacy.128 The primary endpoints were rejection and infection, and the secondary endpoints were liver function, renal function, bone marrow function, cardiovascular risk factors, and the recurrence of hepatitis C. Study treatment was started on postoperative day 2 with mycophenolate mofetil. All patients received an identical steroid taper. Forty-six cyclosporine, modified patients and 44 tacrolimus patients completed the full 4 years of follow-up. The overall patient survival rate was 93%, and the overall graft survival rate was 89%. There were no significant differences seen between the study groups in 4-year patient survival (cyclosporine [modified], 96% versus tacrolimus 90%; p=NS), graft survival (cyclosporine [modified], 90% versus tacrolimus, 88%; p=NS), or rejection (cyclosporine [modified], 34% versus tacrolimus, 24%; p=0.28). There were no differences in infection rates. For patients with hepatitis C (n=37), there were also no differences in viral titers or Knodell biopsy scores; however, in the tacrolimus-treated patients, there was a lower rejection rate (p=0.0097) and a lower rate of hepatitis C recurrence (p=0.05). No difference was seen in the percent of patients weaned off steroids after 4 years or in the incidence of diabetes mellitus and hypertension. More patients in the cyclosporine, modified group had a twofold increase in creatinine when compared to the tacrolimus group (63% versus 38%, respectively; p=0.04).

A prospective randomized trial compared cyclosporine, modified (n=51) to tacrolimus (n=50) for primary immunosuppression.129 One-hundred-one adult liver transplant patients were enrolled and followed for 5 years. At 1, 3, and 5 years, survival rates were 86%, 75%, and 72%, respectively with no significant difference between the 2 treatment arms. A total of thirty cases of acute rejection occurred with no significant difference between the 2 treatment groups. More cyclosporine patients reported serious adverse events than tacrolimus patients (48 versus 32 patients, respectively). More cyclosporine-treated patients (n=19) switched to the other calcineurin inhibitor than tacrolimus-treated patients (n=15). The switch was mainly due of lack of efficacy. There were no cases of chronic rejection in the tacrolimus arm. Four patients were switched from tacrolimus to cyclosporine, modified due to adverse effects. There was no difference between the 2 treatment groups in renal dysfunction, diabetes, hypertension, neurologic disorders, new-onset malignancies or infections, and there were no significant differences in survival or rejection among the intention-to-treat groups.

Cyclosporine, modified (n=250) was compared to tacrolimus (n=245) for safety and efficacy at 3 and 6 months and for patient survival status at 12 months in an open-label, multicenter study involving liver transplant recipients.130 Participants also received steroids with or without azathioprine. At 12 months, 85% of cyclosporine, modified-treated patients and 86% of tacrolimus-treated patients survived with a functioning graft (p=NS). The cyclosporine, modified arm (6%) had significantly fewer hepatitis C-positive patients die or lose their graft by 12 months when compared to the tacrolimus arm (16%;...
p≤0.03). No difference was seen between the groups in recurrence of hepatitis C virus. At 12 months, median serum creatinine concentration was 106 µmol/L in both treatment groups. At 12 months, more tacrolimus-treated patients who were nondiabetic at baseline received antihyperglycemic therapy (13% versus 5%; p≤0.01), and more tacrolimus-treated patients who were diabetic at baseline required anti-diabetic treatment (70% versus 49%; p=0.02). Treatment for de novo or pre-existing hypertension or hyperlipidemia was similar in both groups.

A multicenter, randomized, open-label study compared tacrolimus (n=301) and cyclosporine, modified (n=305) in a total of 606 patients undergoing first orthotopic liver transplantation. Patients in both treatment groups received combined treatment with a standard immunosuppressant regimen. The primary endpoint was the combined frequency of death, retransplantation, or treatment failure. Ninety-six percent of those randomized received the study treatment. An intention-to-treat analysis revealed the primary outcome was reached in 21% (n=62) of patients in the tacrolimus arm versus 32% (n=99) of patients in the cyclosporine, modified arm (relative risk [RR], 0.63; p=0.001). Death occurred in 50 (17%) tacrolimus patients versus 72 (24%) cyclosporine, modified patients; retransplantations were necessary in 11 (4%) versus 31 (10%); and treatment failure for immunological reasons occurred in 6 (2%) versus 12 (4%) patients, respectively. Sepsis and multi-organ failure were the main causes of death in both trial groups. No differences were seen between the 2 groups in the rate of renal dysfunction or the need for antihypertensive therapy; however, more tacrolimus-treated patients developed diabetes mellitus.

**everolimus (Zortress) + reduced-dose tacrolimus (Prograf) versus tacrolimus (Prograf)**

A prospective, multicenter, open-label, parallel group trial randomized adult liver transplant patients at day 30 ± 5 to one of 3 arms, everolimus initiation with tacrolimus elimination (n=231), everolimus plus reduced-exposure tacrolimus (n=245), or a control arm of tacrolimus alone (n=243). The tacrolimus elimination study arm was stopped early due to a higher rate of biopsy-proven acute rejection (BPAR). The primary endpoint looked at a composite of failure rates including BPAR, graft loss, or death at 12 months. A secondary endpoint was the change in renal function measured as change in estimated glomerular filtration rate (eGFR) from randomization to month 12. The percentage of patients receiving mycophenolate mofetil at time of randomization was similar across the 3 groups and mycophenolate mofetil was discontinued according to protocol. The primary efficacy endpoint of BPAR, graft loss, or death at month 12 occurred in 6.5% of patients on the everolimus + reduced tacrolimus arm and in 9.5% of patients on the tacrolimus control arm. This difference (3%) was statistically non-inferior (p<0.001 for the noninferiority test with a noninferiority margin of 12%). There was no difference between the 2 groups in either graft loss or death but the everolimus + reduced tacrolimus group had a significantly lower rate of BPAR 2.9% versus 7% (p=0.035). There was a greater decline in adjusted eGFR from randomization to month 12 in the tacrolimus control arm compared to the everolimus plus reduced tacrolimus arm (difference of 8.5 mL/min/1.73 m²; p<0.001). Discontinuation of study drug due to adverse events occurred more frequently in the everolimus + reduced tacrolimus arm (25.7%) compared to the tacrolimus control arm (14.1%). There was a higher risk of leukopenia and peripheral edema in the everolimus + reduced tacrolimus arm will all other adverse event rates were similar within the 2 groups. At a 24-month follow up, the primary efficacy endpoint (BPAR, graft loss or death was similar between the 2 groups (everolimus + reduced tacrolimus, 10.3%; tacrolimus control, 12.5%). BPAR was less frequent in the everolimus + reduced tacrolimus group at month 24 (6.1% versus 13.3%; p=0.01). Renal function at month 24 as measured by change in eGFR favored everolimus + reduced tacrolimus compared to tacrolimus control (difference
6.7 mL/min/1.73 m²; p=0.002). Everolimus plus tacrolimus was discontinued due to adverse events in 28.6% of patients compared to 18.2% of tacrolimus control patients.

**reduced-dose tacrolimus (Prograf) + mycophenolate mofetil (CellCept) versus standard-dose tacrolimus (Prograf)**

A multicenter, randomized trial of 195 adult patients undergoing first liver transplant was conducted.134 In the control arm of the study, patients received tacrolimus 0.075 mg/kg twice daily and then were dose adjusted to maintain trough whole blood concentrations of tacrolimus ≥ 12 ng/mL for the first 6 weeks, ≥ 10 ng/mL from week 7 to 12, ≥ 8 ng/mL from month 4 to 6 and ≥ 6 ng/mL from month 7 to 12. In the experimental arm, reduced dose tacrolimus was given at half the dose of the control group (0.04 mg/kg twice daily) to maintain whole blood trough levels of tacrolimus ≤ 10 ng/mL for the first 6 weeks, ≤ 8 ng/mL for week 7 to month 6 and ≤ 6 ng/mL from month 7 to 12. In the experimental arm, patients received MMF 1.5 grams twice daily for the first 6 weeks followed by 1 gram twice daily until month 12. Primary outcomes included the incidence of renal dysfunction, arterial hypertension, or diabetes (combined criterion) occurring between week 9 and week 48 post-transplant as well as the incidence of acute graft rejection during the 48-week post-transplantation period. The composite adverse effect criteria of renal dysfunction or arterial hypertension or diabetes occurred in 80% of patients of the control group compared to 64% of patients in the experimental arm (HR, 0.68; 95% CI, 0.49 to 0.95; p=0.021). Leukopenia, thrombocytopenia and diarrhea all occurred at a statistically significantly higher rate in the MMF arm of the trial compared to the standard-dose tacrolimus arm. Acute graft rejection was seen in 46% (control arm) versus 30% (reduced-dose tacrolimus plus MMF arm) of patients (HR, 0.59; 95% CI, 0.37 to 0.94; p=0.024).

**tacrolimus (Prograf) versus cyclosporine plus azathioprine**

An open-label, randomized, non-United States (US) study assessed the efficacy and safety of tacrolimus suspension plus corticosteroids versus cyclosporine, corticosteroids, plus azathioprine in de novo pediatric liver transplant patients ≤ 16 years old (majority < 5 years) (n=181).135 Included patients were assigned to either tacrolimus for oral suspension 0.3 mg/kg/day or cyclosporine 10 mg/kg/day orally beginning 6 hours following transplant surgery, with trough levels targeting 5 to 20 ng/mL. At 12 months, overall failure occurred in 52.7% of those assigned tacrolimus suspension and 61.1% assigned cyclosporine (treatment difference, -8.4%; 95% CI, -22.7 to 6). Notably, safety and pharmacokinetic data with this formulation and population was used to support tacrolimus use in pediatric patients with heart and kidney transplants as well.

**Renal Transplant**

**azathioprine (Imuran) versus cyclosporine**

The long-term effects of azathioprine were compared to cyclosporine in live-donor kidney transplantation patients in a randomized study.136 Adult primary renal transplant recipients aged between 18 and 60 years with 1 haplotype HLA mismatch who had been transplanted before 1988 were included. Four hundred seventy-five participants received a primary immunosuppressive protocol consisting of both steroid and azathioprine (n=300) or cyclosporine (n=175). Study endpoints included patient and graft survival rates, condition at last follow-up, rejection (acute and chronic), and graft function (serum creatinine and creatinine clearance). There was no significant difference between the groups in overall frequency of acute rejection episodes. The azathioprine-treated patients had graft survival rates of 69% versus 58% at 5 years, and 52% versus 36% at 10 years compared to cyclosporine.
treatment. However, at 20 years, graft survival rates had declined to 26% in the azathioprine arm and 24% in the cyclosporine arm. No significant differences were seen between the 2 groups regarding post-transplant malignancies, diabetes mellitus, hepatic impairment, or serious bacterial infections.

Recipients (n=112) of haplo-identical live-related donor kidney transplants were randomly assigned prior to transplantation to receive azathioprine (n=54) or cyclosporine (n=58) combined with prednisone. Patients were followed for 3 to 6 years (mean 50 ± 8 months). Thirteen azathioprine-treated patients (24%) and 6 cyclosporine-treated patients (10%) were switched to the alternate immunotherapy (p≥0.05). No significant differences were seen between the groups in patient survival, graft survival, or overall frequency of acute rejection during the follow-up period. However, the number of patients who had 2 or more rejection episodes was higher among the azathioprine-treated patients (p≤0.04). The mean serum creatinine concentrations were significantly higher in the cyclosporine arm at 1, 12, and 24 months after transplantation.

Azathioprine (Imuran) versus Mycophenolate Mofetil (CellCept)

After cadaveric renal transplant, patients were randomized to receive tacrolimus in combination with either azathioprine (n=59) or mycophenolate mofetil 1 gram per day (n=59) or 2 grams per day (n=58) and followed for 1 year post-transplant. Participants were evaluated for the incidence of biopsy-confirmed acute rejection, patient and graft survival, and adverse events. The tacrolimus dose and trough concentrations were similar between treatment groups at all time points. By 6 months post-transplant, the mean dose of mycophenolate mofetil decreased in the 2 gram group to 1.5 grams, primarily due to gastrointestinal-related adverse effects. The incidence of biopsy-confirmed acute rejection at 1 year was 32.2% in the azathioprine group, 32.2% in the mycophenolate mofetil 1 gram group, and 8.6% in the mycophenolate mofetil 2 grams group (p≤0.01). There was no difference among the 3 groups in the use of antilymphocyte antibodies for the treatment of rejection. The incidence of most adverse events was similar across treatment groups and comparable with previous reports. No differences were seen across the 3 treatment groups in the incidence of malignancies or opportunistic infections.

Antirejection activity and adverse events of mycophenolate mofetil were compared to azathioprine both with cyclosporine, modified and steroids (phase A) in recipients of cadaveric kidney transplants over 6 months in a multicenter, prospective, randomized, parallel-group trial. Participants were then followed for an additional 15 months without steroids (phase B). The primary endpoint, occurrence of acute rejection episodes, was analyzed by intent-to-treat. One hundred sixty-eight patients per group entered phase A. Clinical rejections were seen in 56 patients (34%) assigned to mycophenolate mofetil and 58 patients (35%) assigned to azathioprine (p=0.44). Eighty-eight patients in the mycophenolate mofetil group and 89 in the azathioprine group entered phase B. Clinical rejections were seen in 14 patients (16%) taking mycophenolate mofetil and 11 patients (12%) taking azathioprine (p=0.71).

Azathioprine (Imuran) versus Sirolimus (Rapamune)

A prospective, multicenter, randomized, double-blind trial compared azathioprine to sirolimus added to cyclosporine and prednisone. Recipients (n=719) of HLA-mismatched cadaveric or living-donor renal allografts who displayed initial graft function were randomly assigned to sirolimus 2 mg daily (n=284) or 5 mg daily (n=274) or azathioprine (n=161). At 6 and 12 months, the primary composite endpoint of efficacy failure, occurrence of biopsy-confirmed acute rejection episodes, graft loss, or death and various secondary endpoints that characterize these episodes were compared using an intention-to-treat analysis. The 2 sirolimus groups had a lower rate of efficacy failure at 6 months (2
mg: 18.7%, p=0.002; 5 mg: 16.8%, p≤0.001) compared to azathioprine (32.3%). In addition, the frequency of biopsy-confirmed acute rejection episodes was lower in the sirolimus groups (2 mg: 16.9%, p=0.002; 5 mg: 12%, p≤0.001) compared to azathioprine (29.8%). Survival was similar in all groups for grafts and patients at 12 months. Rates of infection and malignancies were similar among the groups.

cyclosporine versus sirolimus (Rapamune)

The efficacy and tolerability of a calcineurin inhibitor-free regimen was compared in a prospective, randomized trial. One hundred forty-five renal transplant recipients were given either sirolimus (n=71) or cyclosporine (n=74) along with polyclonal antilymphocyte antibodies, mycophenolate mofetil, and steroids for 6 months. Estimated glomerular filtration rates, the primary endpoint, were not statistically different at 12 months between the 2 groups. In addition, patient and graft survival, delayed and slow graft function, incidence of biopsy-proven rejection, and rates of steroid withdrawal were not statistically different between the groups at 12 months. Overall study drop-out rates were 28% with sirolimus and 14.9% with cyclosporine. In patients who remained on treatment according to protocol at 12 months, estimated glomerular filtration rates were significantly higher with sirolimus (69 ± 19 versus 60 ± 14 mL/min; p=0.01). Sirolimus-treated patients had more adverse events such as wound complications, mouth ulcers, diarrhea, hypokalemia, bronchopneumonia, and proteinuria > 0.5 g/24 hours compared to cyclosporine-treated patients (38.8% versus 5.6%; p≤0.001). Additionally, sirolimus-treated patients experienced significantly fewer cytomegalovirus (CMV) infections compared to cyclosporine-treated patients (6% versus 23%; p≤0.01). At an 8 year follow up of this study, 9 patients had been lost to follow up and 99 of the original 145 patients had a functional graft. Over the 8 year time period, 71 patients had their study drug withdrawn and replaced. Sirolimus was withdrawn in 43 patients and replaced by a CNI in 42 of those patients (12 cyclosporine and 30 tacrolimus). Cyclosporine was withdrawn in 28 patients and was most often replaced with tacrolimus. In total, 52% of study patients remained on sirolimus and 73% remained on cyclosporine at 8 years. Almost all patients received either MMF or mycophenolate sodium and the doses were similar between the 2 groups. The majority of patients were no longer receiving corticosteroids at 8 years post-transplant. This follow up study utilized a conditional intention-to-treat (ITT) population defined as those patients who still had a functioning graft at year 8. In this conditional ITT population, eGFR was higher with sirolimus-treated population than with cyclosporine-treated population at year 8 (62.5 ± 27.3 mL/min versus 47.8 ± 17.1 mL/min; p=0.004). There was no difference in graft survival at 8 years among the groups. Overall graft survival was 75.6%, 73.3%, and 77.7% for all patients, sirolimus-treated patients and cyclosporine-treated patients, respectively (p=0.57). The 2 treatment groups did not differ at 8 years in terms of development of malignancy (p=0.76), mean systolic (p=0.787) or diastolic blood pressure (p=0.11) or hemoglobin level. Overall patient survival also did not differ between the groups (86.3%, 90.6%, respectively for the sirolimus-treated and cyclosporine-treated patients; p=0.51).

A 6-month, randomized, open-label, multicenter prospective study was conducted to evaluate the effects of sirolimus (n=33) versus cyclosporine (n=36) each in combination with antithymocyte globulin induction, mycophenolate mofetil, and steroids in recipients of kidney transplant. More sirolimus-treated patients withdrew because of delayed graft function and surgical complications (16 versus 6; p≤0.01). In addition, delayed graft function tended to be more frequent among sirolimus recipients (45.4% versus 30.6%; p=0.22), but graft survival was similar (87.5% versus 97%; p=0.19). At 6 months,
there were no significant differences in biopsy-proven acute rejection or calculated creatinine clearance.

A randomized, prospective trial of 61 adult primary kidney transplant recipients compared sirolimus with cyclosporine.\textsuperscript{144} Each patient received induction therapy with 20 mg basiliximab (Simulect\textsuperscript{®}) on days 0 and 4, and maintenance therapy with mycophenolate mofetil 1 gram twice daily and steroids. Sirolimus doses were titrated to maintain 24-hour trough concentrations of 10 to 12 ng/mL for 6 months and 5 to 10 ng/mL thereafter. Cyclosporine therapy was titrated to maintain 12-hour trough concentrations of 200 to 250 ng/mL. Participants were followed for a mean duration of 18.1 months (range, 12 to 26 months). No differences were seen between the treatment groups in percentages of 1 year patient survival, graft survival, or biopsy-confirmed acute rejection rates. At 6 and 12 months, respectively, sirolimus-treated patients showed significantly better mean serum creatinine concentrations (1.29 and 1.32 mg/dL, respectively) and calculated creatinine clearances (77.8 and 81.1 mL/min, respectively) than cyclosporine-treated patients (1.74 and 1.78 mg/dL, and 64.1 and 61.1 mL/min, respectively; p=0.008 and p=0.004). Significantly higher 1-year trough concentrations of mycophenolic acid were seen in the sirolimus-treated recipients (4.16 ng/mL versus 1.93 ng/mL; p=0.001).

In a study, patients (n=448) were randomly assigned before transplant to receive sirolimus and tacrolimus (SRL+TAC) or sirolimus and cyclosporine (SRL+CsA), each with corticosteroids.\textsuperscript{145} Both treatments demonstrated equivalent efficacy of the composite endpoint at 12 months with efficacy failure rates of 21.9\% versus 23.2\% (SRL+TAC versus SRL+CsA, respectively; p=0.737). Biopsy-confirmed acute rejection rate (13.8\% versus 17.4\%) and graft survival rate (89.7\% versus 90.2\%) were similar. In evaluable patients, renal function was not superior in SRL+TAC versus SRL+CsA (54.5 versus 52.6 mL/min; p=0.466). At 12 months, there were no significant differences in rates of death, discontinuation because of adverse events, hypercholesterolemia, hyperlipidemia, or proteinuria. Diarrhea and herpes simplex infections occurred significantly more often in SRL+TAC patients. Hypertension, cardiomegaly, increased creatinine, overdose (primarily calcineurin inhibitor toxicity), acne, urinary tract disorders, lymphocele, and ovarian cysts occurred significantly more often in SRL+CsA patients.

A prospective, open-label, multicenter randomized study evaluated the conversion of 192 patients from a cyclosporine-based regimen to a sirolimus-based regimen 3 months after transplantation.\textsuperscript{146} All patients were also given mycophenolate mofetil and oral steroids, which were planned to be discontinued after 8 months. The primary endpoint, creatinine clearance week 52, was significantly better in the sirolimus group (68.9 versus 64.4 mL/min; p=0.017). Patient and graft survival were not statistically different. The incidence of acute rejection episodes, mainly occurring after withdrawal of steroids, was not statistically higher in the sirolimus group (17\% versus 8\%; p=0.071). Significantly more patients in the sirolimus group reported aphthous, diarrhea, acne, and high triglyceride concentrations.

A multicenter, prospective trial included 193 kidney recipients randomized at week 12 to switch from cyclosporine to sirolimus or to continue cyclosporine.\textsuperscript{147} All patients received mycophenolate mofetil. Quantified assessment of interstitial fibrosis by a program of color segmentation was performed at 1 year in 121 patients. At 1 year, renal function was significantly improved in the conversion group. Biopsy results, however, showed no between-group difference in percentage of interstitial fibrosis.
An open-label, parallel-group, comparative trial randomized 487 patients 2:1 to sirolimus or cyclosporine. All patients received basiliximab induction as well as maintenance mycophenolate mofetil and corticosteroids along with either sirolimus or cyclosporine. Within 6 months of the start of the trial, an imbalance in the incidence of acute rejection was noted. The data monitoring committee noted the sirolimus trough levels were below the target range in 39% of patients 2 weeks after transplantation. A protocol amendment increased the loading dose of sirolimus. However, the imbalance in acute rejection rates continued despite the protocol amendment and at one year the study was terminated due to the increased BCAR rate in the sirolimus group.

**cyclosporine versus tacrolimus (Prograf)**

Two hundred patients were randomized in a 2:1 fashion to receive tacrolimus (n=134) or cyclosporine (n=66) along with thymoglobulin induction, an antimetabolite, and prednisone. At 1 year, efficacy was similar between the groups. The rate of acute rejection was 4% in the tacrolimus group and 6% in the cyclosporine group. The rate of patient survival was 99% in the tacrolimus group and 100% in the cyclosporine group, and the rate of graft survival was 95% in the tacrolimus group and 100% in the cyclosporine group. Serum creatinine concentrations were lower in the tacrolimus group compared with the cyclosporine group (1.3 ± 0.3 versus 1.6 ± 0.7 mg/dL; p=0.03). The incidences of CMV infection, anti-hypertensive requirement, and post-transplant diabetes mellitus were similar; however, 2 patients in the tacrolimus arm developed malignancy.

A multicenter, randomized trial comparing the 12-month efficacy and safety of tacrolimus-based to cyclosporine-based immunosuppressive regimens in the prevention of renal allograft rejection enrolled 448 renal transplant recipients assigned to receive triple-drug therapy consisting of tacrolimus (n=303) or cyclosporine (n=145), each in combination with azathioprine and low-dose corticosteroids. Results showed that tacrolimus therapy was associated with a significant reduction in the frequency of both acute rejection (tacrolimus 25.9% versus cyclosporine 45.7%; p≤0.001) and corticosteroid-resistant rejection (11.3% versus 21.6%; p=0.001) at 12 months. No significant differences were seen between the groups in 1-year patient survival (tacrolimus, 93% versus cyclosporine, 96.5%; p=0.14) and graft survival rates (82.5% versus 86.2%; p=0.38). The safety profiles of the tacrolimus- and cyclosporine-based regimens were similar. The tacrolimus treatment group reported higher incidences of elevated serum creatinine, tremor, diarrhea, hyperglycemia, diabetes mellitus, and angina pectoris; however, the cyclosporine treatment group reported higher incidences of acne, arrhythmia, gingival hyperplasia, and hirsutism.

In a randomized, open-label study, 412 patients receiving cadaveric kidney transplants were randomized to tacrolimus (n=205) or cyclosporine (n=207) and followed for 1 year. Assessments were done for patient and graft survival and the incidence of acute rejection. One-year patient survival rates were 95.6% for tacrolimus and 96.6% for cyclosporine (p=0.576), and 1-year graft survival rates were 91.2% for tacrolimus and 87.9% for cyclosporine (p=0.289). The incidence of biopsy-confirmed acute rejection was significantly reduced in the tacrolimus group compared with the cyclosporine group (30.7% versus 46.4%; p=0.001). Both treatment groups reported impaired renal function, gastrointestinal disorders, and neurological complications; however, tremor and paresthesia were more frequently reported in the tacrolimus group. The incidence of post-transplant diabetes mellitus was 19.9% in the tacrolimus group and 4% in the cyclosporine group (p≤0.001).

Cyclosporine-treated patients who had an elevated serum creatinine (SCr) at least 3 months post-renal transplantation (n=186) were randomized in a 2:1 fashion to switch to tacrolimus or continue...
cyclosporine. On baseline biopsy, 90% of patients had chronic allograft nephropathy, and baseline median SCr was 2.5 mg/dL in both treatment groups. For patients with graft function at month 24, SCr had decreased to 2.3 mg/dL in the tacrolimus-treated patients and increased to 2.6 mg/dL in the cyclosporine-treated patients (p=0.01). During the follow-up, acute rejection occurred in 4.8% of tacrolimus-treated patients and 5% of cyclosporine-treated patients. The 2 groups were comparable for 2-year allograft survival (tacrolimus 69%, cyclosporine 67%; p=0.7). Tacrolimus-treated patients experienced lower cholesterol and low-density lipoprotein concentrations along with fewer new-onset infections. In addition, cardiac conditions developed in fewer tacrolimus-treated patients compared to cyclosporine-treated patients (5.6% versus 24.3%; p=0.004). The 2 groups did not differ in glucose concentrations, incidences of new-onset diabetes, or new-onset hyperglycemia.

cyclosporine, modified (Gengraf/Neoral) versus tacrolimus (Prograf)

Cyclosporine modified was compared to tacrolimus in a multicenter, randomized, 6-month open-label study involving 560 patients. Patients were given azathioprine and corticosteroids in addition to either tacrolimus (n=287) at an initial oral daily dose of 0.3 mg/kg or cyclosporine, modified (n=273) at an initial oral daily dose of 8 to 10 mg/kg. The proportion of patients with biopsy-proven acute rejection and the time to the event was the primary endpoint. Tacrolimus-treated patients had a lower rate of biopsy-confirmed acute rejection when compared to cyclosporine, modified (56 patients [19.6%] versus 101 [37.3%]; p≤0.0001). Tacrolimus-treated patients also had a lower incidence of biopsy-confirmed corticosteroid-resistant rejection when compared to cyclosporine, modified (27 [9.4%] versus 57 [21%]; p≤0.0001). Crossover between therapies secondary to biopsy-proven rejection was necessary in 1 (0.3%) tacrolimus-treated patient and 27 (10%) cyclosporine, modified-treated patients (p≤0.0001). The 2 treatment groups had similar rates of patient and graft survival and similar renal function. In addition, the overall rates of adverse events were similar in the 2 groups. However, hypertension and hypercholesterolemia were more common in the cyclosporine, modified-treated patients, and tremor and hypomagnesemia were more frequent in the tacrolimus-treated patients.

A prospective, randomized trial compared the effect of cyclosporine, modified to tacrolimus on the development of renal allograft fibrosis, defined as chronic allograft nephropathy (CAN). One hundred two patients undergoing renal transplantation were given either cyclosporine, modified (15 mg/kg per day adjusted to whole-blood trough concentrations of 200 to 300 ng/mL) or tacrolimus (0.2 mg/kg per day adjusted to whole-blood trough concentrations of 8 to 15 ng/mL) in conjunction with steroids and azathioprine. The 2 drugs were compared using concentrations of interstitial fibrosis in relation to observed efficacy and toxicity profiles. No difference was seen between the groups in demographic characteristics, incidence of acute rejection (cyclosporine, modified 36% versus tacrolimus 35%), or steroid-resistant rejection (both 10%). The cyclosporine, modified-treated patients had a significant increase in allograft interstitial fibrosis. There was a higher incidence of insulin resistance in the tacrolimus group; however, this did not reach statistical significance. Cyclosporine was associated with a significant increase in total cholesterol and low-density lipoprotein concentrations, which persisted throughout the study period (p=0.03 and p=0.021, respectively).

everolimus (Zortress) versus mycophenolate mofetil (CellCept)

In a randomized, multicenter, multinational, 12-month, double-blind, double-dummy, open-label, phase 3 trial in de novo renal allograft recipients (n=588), everolimus 1.5 mg or 3 mg daily was compared with mycophenolate mofetil 2 grams daily. Patients also received cyclosporine and corticosteroids as part of a triple immunosuppressive regimen. At 12 months, there were no
statistically significant differences between everolimus 1.5 mg, everolimus 3 mg, and mycophenolate mofetil in the incidence of biopsy-proven acute rejection (23.2%, 19.7%, and 24%, respectively), graft loss (4.6%, 10.6%, and 9.2%, respectively), or death (5.2%, 4%, and 2.6%, respectively). Everolimus 1.5 mg and mycophenolate mofetil were equally well tolerated. Both were better tolerated than everolimus 3 mg. The incidence of CMV infection was significantly lower in patients receiving everolimus 1.5 mg or 3 mg than in those receiving mycophenolate mofetil (5.2%, 7.6%, and 19.4%, respectively; p=0.001).

A 36-month, randomized, parallel-group study compared everolimus 1.5 mg and 3 mg daily with mycophenolate mofetil 2 grams daily in de novo renal transplant recipients (n=583). Patients also received full-dose cyclosporine and corticosteroids after randomization. For at least their first year, patients received study medication according to a double-blinded, double-dummy design before concerns over nephrotoxicity led to an amended open-label design with reduced cyclosporine troughs. Incidences of primary efficacy failure at 36 months (biopsy-proven acute rejection, graft loss, death, or loss to follow-up) were 33.7%, 34%, and 31.1% for everolimus 1.5 mg, everolimus 3 mg/day, and mycophenolate mofetil, respectively (p=0.81). Antibody-treated acute rejection at 36 months was significantly lower with everolimus 1.5 mg than mycophenolate mofetil (9.8% versus 18.4%; p=0.014). Discontinuation for adverse events, including death and graft loss, was more frequent with everolimus compared to the mycophenolate mofetil arm.

**everolimus (Zortress) versus mycophenolate sodium (Myfortic)**

In a 24-month, open-label study, 833 de novo renal transplant recipients were randomized to everolimus 1.5 mg or 3 mg daily with reduced-exposure cyclosporine or mycophenolate 1.44 grams daily plus standard-exposure cyclosporine. Patients received basiliximab (Simulect) with or without corticosteroids. The primary endpoint was composite efficacy failure (treated biopsy-proven acute rejection, graft loss, death, or loss to follow-up) and the main safety endpoint was renal function at month 12 (last observation carried forward). Month 12 efficacy failure rates were non-inferior in the everolimus 1.5 mg and 3 mg versus mycophenolate groups (25.3%, 21.9%, and 24.2%, respectively). Mean eGFR at month 12 was non-inferior in the everolimus groups versus the mycophenolate group. The overall incidence of adverse events was comparable between groups.

**everolimus (Zortress) versus calcineurin inhibitors**

ELEVATE: A 24-month, multicenter, open-label, randomized trial compared select outcomes in patients who convert to everolimus early in therapy (at 10 to 14 weeks) or remain on standard calcineurin inhibitor therapy (cyclosporine or tacrolimus) in 715 de novo kidney transplant recipients also using mycophenolic acid and steroids. The primary endpoint was the change in eGFR from randomization to month 12. The authors found a similar change in eGFR at month 12 (everolimus: mean, 0.3 mL/min/1.73 m² [standard deviation, 1.5]; cyclosporine or tacrolimus: -1.5 mL/min/1.73 m² [standard deviation, 1.5]; p=0.116). BPAR at month 12 occurred more frequently with everolimus versus cyclosporine or tacrolimus (9.7% versus 4.8%; p=0.014); however, this was not statistically significant when compared to the cyclosporine-treated patient subgroup (8.8%; p=0.755). Data also do not suggest a clinically relevant effect on cardiac endpoints.

**mycophenolate sodium (Myfortic) versus mycophenolate mofetil (CellCept)**

Mycophenolate sodium (720 mg twice daily) was compared to mycophenolate mofetil (1,000 mg twice daily) combined with cyclosporine, modified and corticosteroids in 423 de novo kidney transplant recipients. The incidence of biopsy-proven acute rejection was non-inferior in the mycophenolate sodium group (12.3% versus 12.4%; p=0.87). Graft loss, death, or loss to follow-up at 2 years was not significantly different between groups (13.2% versus 14.7%; p=0.23). Mycophenolate sodium was better tolerated than mycophenolate mofetil, with lower incidences of infection-related and other adverse events.
patients in a 12-month, double-blind study. At 6 months, mycophenolate sodium proved to be equivalent to mycophenolate mofetil in efficacy failure, defined by biopsy-proven acute rejection, graft loss, death, or loss to follow up (25.8% versus 26.2% [95% CI, -8.7 to 8]). At 12 months, the incidence of efficacy failure was 26.3% for mycophenolate sodium and 28.1% for mycophenolate mofetil, and the incidence of biopsy-proven acute rejection was 22.5% for mycophenolate sodium and 24.3% for mycophenolate mofetil. The rate of severe acute rejection was 2.1% with mycophenolate sodium and 9.8% with mycophenolate mofetil among those with biopsy-proven acute rejection (p=NS). The incidence of adverse events was similar between the groups. Within 12 months, 15% of mycophenolate sodium and 19.5% of mycophenolate mofetil patients required a dose change due to GI adverse events (p=NS).

In a single-center, open-label, randomized trial, mycophenolate mofetil (group A, n=75) was compared to enteric-coated mycophenolate sodium (group B, n=75) in primary renal transplant recipients receiving combined thymoglobulin/daciluzumab induction along with reduced tacrolimus dosing and elimination of corticosteroids 1 week postoperatively. The primary endpoint was the incidence rate of acute rejection during the first 12 months post-transplant. Secondary aims were to compare graft and patient survival, renal function, drug dosing and monitoring, gastrointestinal adverse effects, and other adverse events at 12 months of follow-up. Patient/grant survival in groups A and B were 100%/96% versus 99%/96%, respectively (p=NS). At 12 months, 3% versus 9% in group A and group B, respectively, experienced biopsy-proven acute rejection (p=NS). Incidence of new onset diabetes mellitus, infections requiring hospitalization, and GI adverse effects appeared equivalent.

**mycophenolate mofetil (CellCept) versus sirolimus (Rapamune)**

The impact on graft survival and long-term graft function in renal transplant recipients using maintenance therapy consisting of either mycophenolate mofetil or sirolimus, each without prednisone, was compared. Induction therapy was given on days 0, 1 and 2 post-transplant. Patients were then prospectively randomized to 2 maintenance immunosuppressive regimens with tacrolimus plus mycophenolate mofetil (n=45) or tacrolimus plus sirolimus (n=37). During the 3-year follow-up, there was 1 kidney loss in the mycophenolate mofetil group versus 6 losses in the sirolimus group (p=0.04). Glomerular filtration rates at different time-points post-transplant were better, and the slope of glomerular filtration rate decline per month was flatter in the mycophenolate mofetil arm compared to the sirolimus arm.

A 1-year, randomized, multicenter clinical trial was conducted comparing the combination of sirolimus (n=185) or mycophenolate mofetil (n=176) with tacrolimus and corticosteroids in kidney transplant patients. The primary endpoint of the study was the incidence of biopsy-confirmed acute rejection at 6 months. Patient and graft survival, renal function, study drug dosing and discontinuations were evaluated at 1 year, and results showed no differences in patient or graft survival. However, patients without delayed graft function receiving mycophenolate mofetil had significantly better graft survival (99% versus 93%; p=0.01), and those receiving a transplant from a live donor had a trend towards better graft survival with mycophenolate mofetil (98% versus 91%; p=0.07). The sirolimus-treated group had a higher incidence of study drug discontinuations (26.5% versus 14.8%; p=0.006). The mycophenolate mofetil-treated patients had better mean serum creatinine concentrations (1.3 mg/dL versus 1.5 mg/dL; p=0.03) and a trend towards higher calculated creatinine clearance (58.4 mL/min versus 54.3 mL/min; p=0.06). More sirolimus-treated patients experienced serum creatinine concentrations greater than 2 mg/dL (20.4% versus 11%; p=0.02).
One hundred kidney transplant recipients receiving tacrolimus-based immunosuppressive regimens were randomized into equal groups and given mycophenolate mofetil 2 grams per day or sirolimus at a loading dose of 150 mg followed by 5 mg daily until day seven and 2 mg daily thereafter.¹⁶⁴ No differences were observed in incidences of the composite primary endpoint, biopsy-confirmed acute rejection, graft loss, and death. In addition, no differences were seen between the groups in biopsy-confirmed acute rejection or 1-year patient, graft, or death-censored graft survival. However, patients treated with sirolimus had a higher mean creatinine (1.6 ± 0.5 mg/dL versus 1.4 ± 0.3 mg/dL; p=0.007), incidence of proteinuria (52% versus 10.7%; p=0.041), mean urinary protein concentrations (0.3 ± 0.5 g/L versus 0.1 ± 0.2 g/L; p=0.012), mean cholesterol (217 mg/dL versus 190 mg/dL; p=0.03), and percentage of premature drop outs (26% versus 8%; p=0.031) when compared to the mycophenolate mofetil-treated patients.

In addition to tacrolimus, 325 participants were given sirolimus 2 mg daily, 325 participants were given sirolimus 0.5 mg daily, and 327 participants were given mycophenolate mofetil 1 gram daily.¹⁶⁵ Initially, the tacrolimus dose was 0.2 mg/kg daily, and the sirolimus loading dose was 6 or 1.5 mg followed by a daily dose of 2 or 0.5 mg. All groups received identical steroid doses. The sirolimus 2 mg group had a lower incidence (15.7%) of biopsy-proven acute rejection compared with the sirolimus 0.5 mg (25.2%; p=0.003) group and the mycophenolate mofetil (22.3%; p=0.036) group. Six-month graft survival was 91% for the sirolimus 2 mg arm, 92.6% for the sirolimus 0.5 mg arm, and 92.4% for the mycophenolate mofetil arm. The respective values for patient survival were 98.1%, 97.8%, and 97.9%. Study drop-out rates due to adverse events were as follows: 34 patients (10.5%) in the sirolimus 2 mg group, 19 patients (5.8%) in the sirolimus 0.5 mg group, and 16 patients (4.9%) in the mycophenolate mofetil group. More patients in the sirolimus 2 mg group experienced hyperlipidemia compared with the sirolimus 0.5 mg and the mycophenolate mofetil group (24%, 19.4%, and 11%, respectively).

ADHERE: A randomized, open-label study compared renal function 1 year following kidney transplant in patients who received either prolonged-release tacrolimus, corticosteroids, or mycophenolate mofetil or prolonged-release tacrolimus and sirolimus (n=569).¹⁶⁶ Initially (through day 27), patients received prolonged-release tacrolimus (initial dose, 0.2 mg/kg/day), corticosteroids, and mycophenolate mofetil, but were randomized thereafter to receive either continued tacrolimus (with dose reduction) and mycophenolate mofetil or tacrolimus plus sirolimus. The primary endpoint was GFR at 52 weeks following transplant. GFR was similar between groups (40.73 versus 41.75 mL/min/1.73 m², respectively; p=0.405). However, 1 secondary endpoint, composite efficacy failure, was higher in the sirolimus-containing therapy group (p=0.002), which was thought to be attributed to increased discontinuation due to adverse effects.

**sirolimus (Rapamune) versus tacrolimus (Prograf)**

A prospective, randomized trial compared the safety and efficacy of sirolimus (target concentration 12 to 18 ng/dL in the first month) to tacrolimus (target concentration 12 to 15 ng/mL in the first month) each combined with mycophenolate mofetil 750 mg twice daily, prednisone tapered to 10 mg per day by 3 months and immunosuppressant induction with thymoglobulin.¹⁶⁷ Preliminary results at 4 months in 85 patients showed acute rejection rate of 7.5% in the tacrolimus group compared to 6.7% in the sirolimus group. Eight sirolimus patients withdrew from the study, most commonly due to wound complications. At 1 month, renal function appeared to be better in the sirolimus group; however, this had not reached statistical significance.
In a prospective, randomized, open-label trial, adult kidney transplant recipients (n=119) received tacrolimus, mycophenolate sodium and prednisone for 3 months post-transplant and were then randomized to either convert tacrolimus to sirolimus (sirolimus/mycophenolate sodium group) or continue on tacrolimus combined with mycophenolate sodium. The trial examined safety and tolerability of these 2 regimens. After randomization, there was no significant difference between the 2 groups in the cumulative incidences of adverse events or serious adverse events. The most common adverse events in both groups were gastrointestinal and infection. There was a significantly higher incidence in the sirolimus/mycophenolate sodium of aphthous ulcers (28% versus 0%; p<0.01), sinustis (10% versus 0%; p=0.01), dermatitis (15% versus 3%; p=0.03) and dyslipidemia (35% versus 14%; p=0.02). Dose reductions due to adverse events occurred in 18.3% of the patients receiving sirolimus/mycophenolate compared to 3.3% of patients receiving tacrolimus/mycophenolate sodium.

**tacrolimus extended-release capsules (Astagraf XL) versus tacrolimus (Prograf)**

A randomized, open-label, multicenter, trial compared tacrolimus ER capsules (Astagraf) to tacrolimus immediate-release over 12 months in patients with a kidney transplant. All patients received basiliximab induction and concomitant treatment with MMF and corticosteroids. Patients 17 to 77 years of age were randomized to receive tacrolimus ER capsules (Astagraf XL) (n=214) 0.15 mg/kg/day or tacrolimus immediate-release (n=212) 0.1 mg/kg/day. The primary efficacy outcome was the percentage of patients who developed biopsy-proven acute rejection (BPAR), graft failure, death, and/or were lost to follow-up at 12 months. In the tacrolimus ER capsule (Astagraf XL) group 30 (14%) patients experienced the combined outcome compared to 32 (15.2%) in the tacrolimus immediate-release group with treatment difference of -1.1% (95% CI, -7.8 to 5.6). Premature discontinuation from treatment at the end of 1 year occurred in 14% of tacrolimus ER capsules (Astagraf XL) patients and 16% of tacrolimus immediate-release patients, primarily due to adverse reactions.

A randomized, double-blind, multicenter, trial of identical trial design with the exception of no basiliximab induction compared tacrolimus ER capsules (Astagraf XL) to tacrolimus immediate-release over 12 months in patients receiving a kidney transplant. All patients received concomitant treatment with MMF and corticosteroids without antibody induction. Patients 18 to 65 years of age were randomized to receive tacrolimus ER capsules (Astagraf XL) (n=331) or tacrolimus immediate-release (n=336) at a pre-operative dose of 0.1 mg/kg/day and a post-operative dose of 0.2 mg/kg/day. After post-operative day 1, the doses were altered to achieve comparable mean tacrolimus trough concentrations between tacrolimus ER capsules (Astagraf XL) and tacrolimus immediate-release. Higher total mean daily doses of tacrolimus ER capsules (Astagraf XL) were required than tacrolimus immediate-release dose, on average by 25%. The primary efficacy outcome was the percentage of patients who developed biopsy-proven acute rejection (BPAR), graft failure, death, and/or lost to follow-up at 12 months. In the tacrolimus ER capsules (Astagraf XL) group 93 (28%) patients experienced the outcome compared to 78 (23%) in the tacrolimus immediate-release group with treatment difference of 4.9% (95% CI, -1.7 to 11.5). Premature discontinuation from treatment at the end of 1 year occurred in 24% of tacrolimus ER capsules (Astagraf XL) patients and 19% of tacrolimus immediate-release patients, primarily due to adverse reactions.

A phase 3 randomized, open-label, comparative, noninferiority study examined 638 patients de novo kidney transplants. Patients were randomized to 1 of 3 treatment arms: tacrolimus ER capsules once daily, tacrolimus twice daily, or cyclosporine twice daily. All patients received basiliximab induction, mycophenolate mofetil and corticosteroids. Patients were followed for 4 years. Four-year Kaplan-Meier estimates of patient survival were 93.2%, 91.2%, and 91.7%, respectively for tacrolimus ER
capsules, tacrolimus immediate-release and cyclosporine arms. Graft survival was 84.7%, 82.7% and 83.9% in these same groups. Adjusted mean differences in renal function, as measured by the Cockcroft-Gault formula, over the 4-year period were not statistically different between tacrolimus ER and tacrolimus immediate-release, but there was a statistically significant difference, favoring tacrolimus ER when compared to cyclosporine (p=0.0118). Evidence of treatment-emergent glucose intolerance in the continuation phase was more common in the tacrolimus ER and tacrolimus immediate-release groups compared to the cyclosporine group. Rates of HbA1c ≥ 6.5% over time were statistically significantly lower in the cyclosporine group compared to the tacrolimus-based groups (log rank test: tacrolimus versus cyclosporine, p=0.01; tacrolimus ER versus cyclosporine, p=0.0006).

tacrolimus extended-release tablets (Envarsus XR) versus tacrolimus (Prograf)

A randomized, open-label trial was conducted in 326 patients who were between 3 months and 5 years post-kidney transplant and who were receiving a stable, therapeutic dose of tacrolimus immediate-release (Prograf). Patients were randomized to once daily tacrolimus ER tablets or maintained on twice daily IR tacrolimus. Concomitant mycophenolate, azathioprine, and/or corticosteroids were allowed. The efficacy failure rates (patients who developed biopsy proven acute rejection, graft failure, death, and/or lost to follow up) at 12 months did not differ between the 2 groups (0%; 95% CI, -4.2 to 4.2), nor did the eGFR at 12 months.

Adult kidney transplant recipients (n=543) were enrolled in a prospective, double-blind, 24-month, phase 3 trial with patients being randomized to either once daily tacrolimus ER at a starting dose of 0.17 mg/kg/day or tacrolimus IR 0.1 mg/kg /day given twice-daily. Doses were adjusted to maintain whole blood trough concentrations within the range of 6 to 11 ng/mL for the first 30 days and then 4 to 11 ng/mL for the remainder of the study. All patients also received a mycophenolate preparation, an interleukin-2 receptor antagonist, and corticosteroids per local protocols. Efficacy endpoints included treatment failures which included any of the following: death, transplant failure, BPAR, or loss to follow up within 24 months after randomization). Safety endpoints included incidence of adverse events, including serious adverse events, as well as drug discontinuations due to adverse events. At 24 months, treatment failure was 23.1% for patients in the tacrolimus ER group and 27.3% in the tacrolimus IR group. This difference of 4.14%, (95% CI, -11.38% to 3.17) was below the defined non-inferiority margin of 10%. Overall patient survival was 95.9% versus 95.2% (p=0.7), respectively, and transplant survival was 95.8% versus 94.4% (p=0.4), respectively. The incidence of adverse events was similar between the 2 groups as was the proportion of patients who discontinued the study drug due to adverse events. A total of 61.9% and 67.3% of patients experienced serious adverse events in the tacrolimus ER and tacrolimus IR groups, respectively, with the highest percentage of serious adverse events related to urinary tract infections or kidney transplant rejection.

Psoriasis

cyclosporine (Sandimmune) and cyclosporine, modified (Neoral)

Patients with severe, chronic, plaque-type psoriasis were randomized on a 1:1 basis to 24 weeks of cyclosporine, modified (n=152) or cyclosporine (n=157) at a starting dose of 2.5 mg/kg per day. Dose increases were allowed after 4 weeks to maintain efficacy, and for patients who achieved remission, dose decreases were allowed after 16 weeks at 4-week intervals. The maximum permitted dose for each formulation was 5 mg/kg per day. Since remission rates were higher for cyclosporine, modified during the first 8 weeks of treatment, it was concluded that cyclosporine, modified produced a more
rapid response than cyclosporine. The number of dose reductions for safety was similar in both groups; however, there were more dose increases to maintain efficacy in the cyclosporine group than the cyclosporine, modified group. There were no differences between groups in the frequency or type of adverse events seen. The mean dose required to control disease was 10% lower with fewer dose adjustments needed in the cyclosporine, modified group than in the cyclosporine group.

**Rheumatoid Arthritis**

*azathioprine (Imuran) versus methotrexate*

Azathioprine was compared to methotrexate in a randomized, double-blind fashion for the treatment of patients with RA in whom parenteral gold and/or D-penicillamine treatment had been ineffective. Participants were given azathioprine (n=33) 100 mg daily or methotrexate (n=31) 7.5 mg weekly for 8 weeks. After 8 weeks, the dosage was increased if needed based on clinical improvement for a total intervention time of 48 weeks. Treatments were compared at 24 weeks with baseline values and showed improvements in 12 of 13 disease variables in the methotrexate group and in 6 of 13 in the azathioprine group. A significant overall clinical improvement, measured by disease activity score, was found in 7 of 20 patients treated with azathioprine and 18 of 30 treated with methotrexate after 24 weeks of treatment. At 48 weeks, a significant overall clinical improvement was seen in 6 of 12 azathioprine-treated patients and 19 of 25 methotrexate-treated patients. The number of dropouts due to adverse events was significantly higher in the azathioprine group. After 48 weeks, 12 azathioprine-treated patients (36%) and 25 methotrexate-treated patients (81%) were still using the initial therapy.

Sixty-four patients with active RA who either had not responded to or who had intolerable adverse effects with parenteral gold and D-penicillamine where given either azathioprine 100 mg daily or methotrexate 7.5 mg weekly in a double-blind, randomized 48-week trial. After 8 weeks of therapy, the dose was increased to either azathioprine 150 mg daily or methotrexate 15 mg weekly. Clinical and laboratory assessments were done every 4 weeks for the first 24 weeks then every 8 weeks for the remainder of the 48 week trial by the same physician. Initial radiologic scores were comparable in both groups and correlated with disease duration. An intention-to-treat analysis after 24 weeks showed significantly fewer new erosions in the methotrexate group compared to the azathioprine group (2 [95% CI, 0.2 to 3.9] and 48 (3.5 [95% CI, 1.3 to 5.8])). After 24 weeks, the change in joint score was also significantly less pronounced in the methotrexate group than in the azathioprine group (difference, 2.8 [95% CI, 0.2 to 5.2]). After 48 weeks, the change in joint score was significantly less pronounced in the methotrexate-treated patients compared to the azathioprine-treated patients as well (difference 3.9 [95% CI, 0.3 to 7.4]). Ten percent of the azathioprine group had reached radiologic stabilization after 48 weeks compared to 29% of the methotrexate group.

*cyclosporine versus azathioprine (Imuran)*

Patients with severe RA were randomized to receive cyclosporine (n=25) or azathioprine (n=27) for 6 months. The initial mean dose of cyclosporine was 4.2 mg/kg and the initial mean dose of azathioprine was 1.7 mg/kg. At 6 months, the mean dose of cyclosporine was 3.4 mg/kg and the mean dose of azathioprine was 1.9 mg/kg. Both treatment groups exhibited statistically significant improvement in standard outcome parameters compared to baseline values. However, there were no statistically significant differences in these same parameters between the 2 study groups. Although no
one withdrew due to impaired renal function, there was a mean increase in serum creatinine associated with cyclosporine.

A prospective, randomized, double-blind, multicenter study compared cyclosporine (starting dose 5 mg/kg) to azathioprine (1.5 to 2 mg/kg) in 117 patients with RA. Ninety-two patients completed the 6-month study. Results showed mean improvement rate using the Ritchie-Index of 8.2, morning stiffness of 41.6 minutes, grip strength of 10.9 mmHg, and swollen joint count of 28.9% in cyclosporine-treated patients compared to 7.7, 28.4 minutes, 15.2 mmHg, and 27.9%, respectively in the azathioprine-treated patients. Treatment was discontinued early in 12 patients in each group. No differences in the efficacy or safety outcomes measured reached statistical significance.

**cyclosporine (Sandimmune) and cyclosporine, modified (Neoral)**

A 52-week, double-blind, multicenter, parallel-group study involving 51 patients with RA receiving stable conventional cyclosporine maintenance treatment was conducted. Participants were randomized to continue conventional therapy (n=27) or to convert to cyclosporine, modified (n=24). Cyclosporine trough blood concentrations were measured before conversion and at specified intervals after conversion. Cyclosporine area under the curve at steady-state was assessed at 1 week before and 6 weeks after randomization in 15 patients in each treatment arm. Cyclosporine doses were titrated as needed based on disease activity and clinical evaluation in both groups. The initial mean daily doses of cyclosporine were 3.5 mg/kg per day compared to 3.3 mg/kg per day in the cyclosporine, modified group and did not change significantly during the study period. The mean bioavailability was 23% higher in the cyclosporine group compared to the cyclosporine, modified group; however, cyclosporine, modified had a more reproducible pharmacokinetic profile. Results were similar for overall incidence and nature of adverse events and changes in vital signs and laboratory variables. There was no significant difference in efficacy between the groups, and no loss of efficacy or intolerability was seen when recipients were switched from cyclosporine to cyclosporine, modified.

**Lymphangioleiomyomatosis (LAM)**

**sirolimus (Rapamune) versus placebo**

A total of 89 patients with LAM who had moderate lung impairment were randomized in a double blind trial comparing sirolimus with placebo. Patients were treated for 12 months followed by a 12 month observation period. The primary end point was the difference between the groups in the rate of change (slope) for forced expiratory volume in 1 second (FEV₁). During the 12-month treatment period, the FEV₁ slope was 12 ± 2 mL per month in the placebo group and 1 ± 2 mL per month in the sirolimus group (p<0.001). The absolute mean change in FEV₁ during the treatment period between the 2 groups was 153 mL or approximately 11% of the mean FEV₁ at enrollment. The sirolimus group had improvement from baseline to 12 months in forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), functional performance and quality of life compared to the placebo group. There was no significant difference between the 2 groups in 6-minute walk distance or diffusing capacity of the lung for carbon monoxide. After discontinuation of sirolimus, the decline in lung function for the previously treated sirolimus group paralleled the placebo group decline. Adverse events were more common in the sirolimus group but the frequency of serious adverse events did not differ significantly between the 2 groups.
META-ANALYSES

A meta-analysis of 20 retrospective studies involving 4,580 patients assessed risk factors for the development of new onset diabetes mellitus (NODM) after liver transplantation. Regarding drug therapy, the results revealed the use of tacrolimus was found to be a significant risk factor (OR, 1.34; 95% CI, 1.03 to 1.76; p=0.03). Other non-drug related factors found to be significantly associated with the development of NODM included hepatitis C virus infection, a family history of diabetes, male gender, impaired fasting glucose, and a high body mass index.

The safety and efficacy of cyclosporine versus tacrolimus for immunosuppression following kidney transplantation was reviewed in a meta-analysis that included 27 randomized, controlled trials involving 6,137 patients. Efficacy parameters included patient mortality, graft loss, and incidence of acute rejection. The safety evaluation included the incidence of new onset diabetes, infection rates, hypertension and hypercholesterolemia. No difference was found in overall patient mortality, (5.5% for tacrolimus-treated patients versus 6.4% for cyclosporine-treated patients, RR=0.84; 95% CI, 0.69-1.02, p=0.08). Likewise, no difference was found between the 2 groups of patients in terms of graft loss (RR=0.87; 95% CI, 0.74-1.03, p=0.10). There was a significant difference in terms of acute rejection with more cyclosporine-treated patients experiencing an incidence of acute rejection compared to tacrolimus-treated patients. This higher incidence of acute rejection in cyclosporine-treated patients compared to tacrolimus-treated patients was true for most time points examined and was statistically significantly different at 6 months, 1 year, 2 years and 5 years (overall, RR=0.55; 95% CI, 0.48-0.63, p<0.00001). There was no difference noted in the incidence of infection or hypertension between the 2 groups (RR=0.96; 95% CI, 0.89-1.04, p=0.31 and RR=0.92; 95% CI, 0.84-1.02, p=0.11 for infection rate and hypertension, respectively). Eleven of the 27 included trials examined the incidence of diabetes and found that patients treated with tacrolimus had an overall higher incidence of diabetes (RR=1.38; 95% CI, 1.06-1.79, p<0.01). The incidence of hypercholesterolemia was reported in only 7 of the 27 studies and found there was a significant decrease in the risk of hypercholesterolemia with cyclosporine at 6 months (RR=1.68; 95% CI, 1.02-2.76, p=.04) but this risk was reversed, with tacrolimus showing a lower incidence of hypercholesterolemia at 1 year (RR=0.67; 95% CI, 0.50-0.90, p=0.008) and at 5 years post-transplant (RR=0.54; 95% CI, 0.36-0.81, p=0.003). This meta-analysis also included a pharmacoeconomic analysis.

A Cochrane network meta-analysis assessed maintenance immunosuppression for adults undergoing liver transplantation (review; 26 trials, n=3,842; outcomes: 23 trials, n=3,693). Various treatments included cyclosporine, everolimus, sirolimus, and tacrolimus. While quality was considered overall low and bias was considered high-risk for the trials, there was no evidence of difference in mortality or graft loss between the different maintenance immunosuppressive regimens (although a difference was found in a single trial). There also was no difference in the proportion of people with serious adverse events, proportion of people with any adverse events, chronic kidney disease, and graft rejections. Notably, the number of adverse events was lower with cyclosporine compared to many other immunosuppressive regimens but the risk of retransplantation was higher with cyclosporine compared to tacrolimus.

A systematic review and meta-analysis compared the eGFR at 12 months and other outcomes in adult kidney transplant patients who had received extended-release once daily tacrolimus to those who had received twice daily tacrolimus (11 randomized, controlled trials). No difference was found between the 2 groups in eGFR at 12 months (mean difference, -0.77 mL/min/1.73m²; 95% CI, -2.41 to 0.87;
p=0.56; I²=0; 4 trials; n=1,738). No significant differences were seen in eGFR, CrCl, SCr, or graft or patient survival at various times over 4 years post-transplant; thus, the authors concluded that the formulations appear comparable.

**SUMMARY**

Currently marketed oral immunosuppressants are primarily utilized in the setting of organ transplantation. Azathioprine and cyclosporine are approved for the treatment of rheumatoid arthritis and cyclosporine is approved for the treatment of plaque psoriasis; however, these agents are used infrequently for these disorders with the advancements that have been made in the treatment of these conditions. Cyclosporine is more commonly used in the treatment of more severe or refractory psoriasis. Sirolimus (Rapamune) is the only FDA-approved treatment for the rare, progressive disease, lymphangioleiomyomatosis (LAM), to help stabilize lung function.

The goal of immunosuppressant therapy in a transplant patient is to prolong graft survival, minimize episodes of rejection and improve overall survival while minimizing adverse effects of the drug. While guidelines for kidney transplantation suggest tacrolimus as the first-line calcineurin inhibitor and mycophenolate as the first-line antiproliferative agent, the best immunosuppressant regimen for a transplant patient should be one individualized based on adverse effect profile, tolerability, type of organ transplanted, and rejection patterns.

The use of corticosteroids has historically been a part of most immunosuppressant regimens. While corticosteroids are still widely utilized during induction phases of immunosuppression and to treat acute or chronic graft rejection, the goal is to minimize their utilization during long-term maintenance therapy due to the adverse effects seen with long-term therapy.

Cyclosporine (Gengraf, Neoral, Sandimmune) and tacrolimus (Prograf, Astagraf XL, Envarsus XR) are effective calcineurin inhibitors with a well-established role in the prophylaxis of organ rejection. While treatment with any formulation of cyclosporine has been found to reduce the incidence of graft rejection, the Gengraf and Neoral formulations are preferred due to their more reliable pharmacokinetic profiles, which result in greater ease of monitoring. Blood concentration of calcineurin inhibitors are routinely monitored in order to keep patients in a therapeutic range that maximizes antirejection properties while minimizing adverse effect potential. Cyclosporine has been used successfully to prevent rejection in heart, liver and renal transplantation, but tacrolimus is often used instead, especially in renal transplantation, due to the established nephrotoxic effects of cyclosporine. Two extended-release tacrolimus preparations (Astagraf XL, Envarsus XR) offer once-daily dosage options in renal transplantation. Cyclosporine is still, however, a preferred agent in heart and heart/lung transplants.

In the setting of renal transplantation, current standard induction protocols followed by a maintenance regimen of a calcineurin inhibitor plus an antiproliferative agent and corticosteroids have resulted in 1 year graft survival rate of approximately 90% and acute rejection rates of 20% or less. However, the calcineurin inhibitors, cyclosporine and tacrolimus, are associated with nephrotoxicity as well as other long-term toxicities. Recent protocols are exploring the outcomes associated with calcineurin inhibitor-free or calcineurin inhibitor-reduced exposure, often by including an mTOR inhibitor such as sirolimus (Rapamune) or everolimus (Zortress) into the immunosuppressant regimen to try and improve both short- and long-term efficacy and safety outcomes.
Mycophenolate (CellCept, Myfortic) has replaced azathioprine (Imuran) in conventional maintenance immunosuppressant regimens because it is less likely than azathioprine to induce severe bone marrow depression.

REFERENCES

1 Azasan [package insert]. Raleigh, NC; Salix; March 2018.
2 Imuran [package insert]. East Brunswick, NJ; Casper; December 2018.
3 Sandimmun [package insert]. East Hanover, NJ; Novartis; March 2015.
4 Gengraf [package insert]. North Chicago, IL; AbbVie; October 2018.
5 Neoral [package insert]. East Hanover, NJ; Novartis; March 2015.
6 Zortress [package insert]. East Hanover, NJ; Novartis; August 2018.
7 CellCept [package insert]. South San Francisco, CA; Genentech; August 2018.
8 Myfortic [package insert]. East Hanover; April 2016.
10 Prograf [package insert]. Northbrook, IL; Astellas; December 2018.
11 Astagraf XL [package insert]. Northbrook, IL; Astellas; November 2018.
12 Envarsus XR [package insert] Edison, NJ; Veloxis; December 2018.
24 Imuran [package insert]. East Brunswick, NJ; Casper; December 2018.
25 Sandimmun [package insert]. East Hanover, NJ; Novartis; March 2015.
26 Gengraf [package insert]. North Chicago, IL; AbbVie; October 2018.
27 Neoral [package insert]. East Hanover, NJ; Novartis; March 2015.
28 Zortress [package insert]. East Hanover, NJ; Novartis; August 2018.
29 CellCept [package insert]. South San Francisco, CA; Genentech; August 2018.
30 Myfortic [package insert]. East Hanover, NJ; Novartis; April 2016.
32 Prograf [package insert]. Northbrook, IL; Astellas; December 2018.
33 Astagraf XL [package insert]. Northbrook, IL; Astellas; November 2018.
34 Envarsus XR [package insert] Edison, NJ; Veloxis; December 2018.
37 Imuran [package insert]. East Brunswick, NJ; Casper; December 2018.
38 Sandimmun [package insert]. East Hanover, NJ; Novartis; March 2015.
39 Gengraf [package insert]. North Chicago, IL; AbbVie; October 2018.
40 Neoral [package insert]. East Hanover, NJ; Novartis; March 2015.
41 Zortress [package insert]. East Hanover, NJ; Novartis; August 2018.
42 CellCept [package insert]. South San Francisco, CA; Genentech; August 2018.
43 Myfortic [package insert]. East Hanover, NJ; Novartis; April 2016.
Myfortic [package insert]. East Hanover, NJ; Novartis; April 2016.
111 Prograf [package insert]. Northbrook, IL; Astellas; December 2018.
112 Astagraf XL [package insert]. Northbrook, IL; Astellas; November 2018.
113 Envarsus XR [package insert] Edison, NJ; Veloxis; December 2018.
135 Prograf [package insert]. Northbrook, IL; Astellas; December 2018.
169 Astgraf XL [package insert]. Northbrook, IL; Astellas; December 2015.
170 Astgraf XL [package insert]. Northbrook, IL; Astellas; December 2015.